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ABSTRACT  
   
Alzheimer’s Disease (AD) is a debilitating neurodegenerative disease. The 
disease leads to dementia and loss of cognitive functions and affects about 4.5 
million people in the United States. It is the 7
th
 leading cause of death and is a 
huge financial burden on the healthcare industry. There are no means of 
diagnosing the disease before neurodegeneration is significant and sadly there is 
no cure that controls its progression. The protein beta-amyloid or Aβ plays an 
important role in the progression of the disease. It is formed from the cleavage of 
the Amyloid Precursor Protein by two enzymes – β and γ-secretases and is found 
in the plaques that are deposits found in Alzheimer brains.  
This work describes the generation of therapeutics based on inhibition of 
the cleavage by β-secretase. Using in-vitro recombinant antibody display libraries 
to screen for single chain variable fragment (scFv) antibodies; this work describes 
the isolation and characterization of scFv that target the β-secretase cleavage site 
on APP. This approach is especially relevant since non-specific inhibition of the 
enzyme may have undesirable effects since the enzyme has been shown to have 
other important substrates. The scFv iBSEC1 successfully recognized APP, 
reduced β-secretase cleavage of APP and reduced Aβ levels in a cell model of 
Alzheimer’s Disease. 
This work then describes the first application of bispecific antibody 
therapeutics to Alzheimer’s Disease. iBSEC1 scFv was combined with a 
proteolytic scFv that enhances the “good” pathway (α-secretase cleavage) that 
results in alternative cleavage of APP to generate the bispecific tandem scFv – 
  ii 
DIA10D. DIA10D reduced APP cleavage by β-secretase and steered it towards 
the “good” pathway thus increasing the generation of the fragment sAPPα which 
is neuroprotective.  
Finally, treatment with iBSEC1 is evaluated for reduced oxidative stress, 
which is observed in cells over expressing APP when they are exposed to stress. 
Recombinant antibody based therapeutics  like scFv have several advantages 
since they retain the high specificity of the antibodies but are safer since they lack 
the constant region and are smaller, potentially facilitating easier delivery to the 
brain. 
  iii 
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Chapter 1 
Introduction 
1.1 Background and Introduction to Alzheimer’s Disease    
Alzheimer‟s disease (AD) is one of the most prominent and devastating 
neurodegenerative diseases associated with aging. AD causes progressive neuronal loss 
that destroys several functions of the brain resulting in dementia eventually leading to 
incapacitation and death. Over the years, several advances in medicine and technology 
have contributed to a dramatic increase in overall life expectancy (49 years to 75 years) 
in the United States resulting in an increase in the number of people developing late-life 
memory disorders associated with neurodegeneration 
1
. About 5.4 million people live in 
the United States with this disease and this number is expected to double in the year 2020 
and triple by 2050. Currently, the amount of money being spent for treatment and care 
associated with Alzheimer‟s Disease in the United States is about a 100 billion dollars 2. 
The disease is a huge financial burden and this is projected to increase significantly 
unless we find an effective cure for the disease. Caregivers are believed to be providing 
17 billion hours of unpaid care valued at $202 billion. AD is the 6
th
  leading cause of 
death in the U.S and the only cause of death in the top 10 for which there is no cure or 
method to slow down progression 
3
.Figure 1.1 is a collection of self portraits of an artist 
named William Ultermohlen who was later diagnosed with Alzheimer‟s disease. The 
progression of the disease can clearly be seen through his artwork. 
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Figure 1.1 Self portraits by artist William Ultermohlen. The series of images 
illustrate his self-decline into dementia over a period of 30 years 
(http://www.williamutermohlen.org) 
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Alzheimer‟s disease commonly affects people over the age of 65 (late onset AD). 
Most patients start showing signs of short term memory loss at the earlier stages of the 
disease. The exact time of onset of the disease is hard to determine. Loss of memory is 
followed by loss in speech, language and muscle strength and co-ordination eventually 
leading to death 
2
. AD was first described by Dr. Alois Alzheimer in 1906. He observed 
characteristic lesions in the brain of a female patient which we now call plaques. In 1960, 
the lesions found in the brains of Alzheimer‟s patients were further characterized as 
plaques and tangles. Further research led to the observation that neurons synthesizing 
acetyl-choline were being lost in the brains of these patients 
4
.  While some cases of AD 
are linked with genetic mutations (Familial forms of AD), most of the cases observed are 
sporadic and in addition, several environmental or health related factors can trigger the 
process of neurodegeneration 
5
. The only way to confirm the disease is to analyze a post 
mortem brain. However, dementia and memory issues can be used to characterize the 
onset of the disease. Further, there exists no method to cure the disease. Current 
therapeutic options for treatment are based on acetylcholinesterase inhibitors which 
increase the levels of acetylcholine in the synapses 
1
.  These treatment options control the 
symptoms but do not target the cause of neurodegeneration. In order to effectively treat 
patients with AD, we need safe and effective therapeutics that will control not just the 
symptoms but also interfere with disease progression 
6
. In addition, this field has been 
crippled by the lack of biomarkers and related diagnostic agents that can help with early 
identification of the disease in order to take maximum advantage from various 
therapeutic strategies 
7; 8
.  
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 1.2 Neuropathology of Alzheimer’s Disease 
The brains of AD patients show significant shrinkage when compared with 
normal brains. Significant reductions are evident in particular regions of the brain 
including the cerebral cortex and the hippocampus. Different parts of the cortex are 
associated with different functions of the brain. The hippocampus  is associated with 
building new memories. Atrophy in the brain also results in fewer synaptic connections 
and loss of neurons. AD brains develop two characteristic lesions called neurofibrillary 
tangles (intracellular) and neuritic plaques (extracellular).
9
. Plaques form as deposits 
between neurons and are composed of aggregated forms of a protein named beta-amyloid 
10
. Beta-amyloid is a primarily 40/42 amino acid long protein with the longer form of the 
protein more prone to aggregation. Deposition of fibrillar forms of Aβ results in the 
formation of spherical plaque deposits which are about 8 nm in diameter. These plaques 
are also associated with reactive microglia and astrocytes 
1
. Similarly, intraneuronal 
tangles contain filamentous structures which are paired helical fragments containing the 
microtubule associated protein – Tau 11. Tau helps the polymerization of tubulin and 
plays a physiological role in maintaining structural stability in neurons. 
Hyperphosphorylation of tau results in dissociation and formation of paired helical 
fragments ultimately leading to the formation of neurofibrillary tangles 
12
.  
Protein misfolding and aggregation as observed with Aβ and tau in AD is also 
common in several other diseases. Many proteins can form similar amyloid aggregates, 
generating b-sheet rich structures. These amyloidogenic proteins can form either 
extracellular deposits called amyloid plaques as in the case of Alzheimer‟s disease or 
5 
intracellular deposits called inclusions 
13
. In the case of Parkinson‟s disease, these 
inclusions are called Lewy Bodies 
14
. A list of some other diseases with a common 
mechanism of amyloid deposition is shown in Table 1.1 
15; 16; 17
.  
Table 1.1 
Amyloidogenic proteins involved in pathogenesis of different amyloid diseases.  
 
 
 
 
 
 
 
 
 
 
 
 
  
Amyloid Diseases Protein involved in the pathogenesis 
Alzheimer‟s Disease Amyloid-beta 
Parkinson‟s Disease Alpha-synuclein 
Huntington‟s Disease Huntingtin 
Bovine Spongiform Encephelopathy Prion proteins 
Type 2 Diabetes Mellitus IAPP 
Creutzfeldt-Jacobs Disease Prion proteins 
6 
Most cases of AD are termed late onset but in a few cases the disease strikes early 
(before the age of 40) which is called early onset AD 
18
. Previous experiments showed 
that acetylcholine producing neurons were affected by the disease and acetyl 
cholinesterase inibitors are currently the approved therapy for AD 
19
. However, these 
therapeutics work only to control the symptoms but do not affect the process of Aβ and 
recently, clinical trials using these inhibitors and NMDA antagonists failed 
20
. Disease 
modifying therapeutics that target generation of Aβ are currently being actively pursued 
for treating AD and several are in clinical trials 
21
. 
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Figure 1.2 Amyloid plaques and neurofibrillary tangles characteristic to AD. The 
images clearly contrast brain pathology of a normal and a AD patient 
22
. 
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1.3 Molecular Basis of Neurodegeneration 
1.3.1 The role of β-amyloid in Alzheimer’s Disease 
While the cause of AD is still unknown, the most accepted theory, the "Amyloid 
Cascade Hypothesis", states that Aβ plays an important role in the pathogenesis of AD. 
Several phenomena support the Amyloid cascade hypothesis. Aβ40/42 are highly 
hydrophobic proteins that tend to aggregate and form smaller oligomers and eventually 
large insoluble fibrils. These fibrils are found in plaques that are observed in AD brains. 
The aggregation and deposition of the protein Aβ is considered to be one of the important 
events that occur in the early stages of the AD 
23
. Down syndrome is caused by trisomy 
of the 21st chromosome and since the APP gene is also present on the 21st chromosome, 
these patients also show increased deposition of Aβ aggregates. Mutations like the 
Swedish mutation (occurring at the beginning of the Aβ sequence) result in increased 
formation of Aβ protein and fibrils resulting in an early onset of familial AD 24. The 
Swedish mutation was first discovered in a Swedish family. People who carry the 
Swedish mutated APP make larger amounts of Aβ. This results in an early deposition of 
Aβ aggregates and early onset of the disease by the age of 40. Transgenic mice that 
overexpress APP develop plaques, progressive neurodegeneration and symptoms of AD.  
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Figure 1.3 A representation of the amyloid cascade hypothesis, illustrating the 
central role of Aβ in the pathogenesis of AD 2. 
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1.3.2  Oligomeric aggregates of Aβ and their role in neurodegeneration 
The greatest argument against the amyloid cascade hypothesis and the role of Aβ 
in AD, has been the lack of correlation between the density of amyloid plaques and the 
symptoms of the disease recorded in patients. Recently, research has shown that plaques 
may not be the principal pathology leading to neuronal injury 
5
. AD brains also have 
diffuse plaques containing soluble aggregates of Aβ. Rather than simply counting 
plaques, accounting for Aβ levels including soluble Aβ species has been shown to 
correlate much better with the extent of memory loss/loss of cognition in AD. Monomeric 
forms of Aβ aggregate to form smaller intermediate soluble species called oligomers 
which further aggregate to form insoluble fibrils 
25
. 
One of the important issues related to therapeutic development is the lack of 
reliable early diagnostic techniques for Alzheimer‟s Disease. This will ensure that the 
disease is identified before it destroys synaptic connections and causes significant 
neuronal damage. It is important to identify the causative agents of early dysfunction in 
AD at the stage where mild symptoms of impairment manifest themselves and try to 
neutralize the same. Soluble oligomers of Aβ are formed much earlier and could be the 
early biochemical species involved in triggering neurotoxicity in AD before the 
histopathology is observed 
26
.  Soluble oligomers have been shown to result in toxicity to 
neuronal cells and might be involved in much earlier events involved in the disease. 
Different types of Aβ oligomers have been reported in previous research and given 
various names including Aβ Derived Diffusable Ligands (ADDLs), Protofibrils, Annular 
doughnut like assemblies, secreted natural oligomers and a 56 kDa species termed Aβ*56 
11 
26; 27; 28
. Synthetic Aβ oligomers have been shown to be toxic to SHSY-5Y neuronal cells 
and bind synapses as well 
29
.  
Table 1.2 
Different Aβ oligomers reported in Alzheimer‟s Research 30 
Name of the 
Oligomeric Species 
Detailed description 
LMW oligomers SDS- stable Low molecular weight oligomers < 8 mers like 
those prepared from CHO-APP cells and from AD brains. 
Shown to inhibit LTP and induce neuronal damage. 
ADDLs Globular aggregates(also called globulomers) initially thought 
to be 10-12mers but shown to be much larger in size like 
protofibrils and include a heterogeneous range of sizes 
Protofibrils Metastable heterogeneous β-sheet rich pre-fibrillar structures 
that bind Congo Red to a lesser extent 
Annular Oligomers Donut shaped structures which an outer diameter of about 8-12 
nm and inner diameter about 2 nm 
Protofilament Structural sub-unit of a fibril which appears like a twisted 
thread and has periodic helical arrangement 
Aβ*56 56 kD assembly of Aβ that impairs learning and memory in 
mouse models of AD 
12 
Aβ*56 is a 56 kD soluble SDS stable assembly of Aβ was found to disrupt 
learning and memory in middle aged Tg2576 mice. Natural and brain derived Aβ 
oligomers can disrupt synaptic transmission 
26
 . Electrophysiological studies in live rats 
and in hippocampal slices has shown that stimulation of synaptic pathways results in 
prolonged firing between neurons. This in turn is believed to lead to synaptic plasticity 
and learning. This phenomenon is called Long Term Potentiation (LTP). Aβ oligomers 
have been shown to inhibit LTP and disrupt learning and memory in animal models  of 
Alzheimer‟s Disease31.  Different kinds of receptors and ionotropic glutamate receptor 
found in the brain. NMDA receptors require both glutamate binding and depolarization of 
the post-synaptic receptor in order to activate the ion channel. Influx of calcium through 
NMDA receptors play a very important role in synaptic plasticity which contributes to 
learning and memory.  
Spines are regions on dendrites where synapses are formed with axons. Dendrites 
have several hundreds of spines and they are the point of contact between neurons.  Aβ 
oligomers have also been shown to reduce the number of spines on dendrites in 
pyramidal hippocampal neurons. When incubated with purified oligomers from media of 
CHO cells over expressing APP, a significant decrease in spine number was observed. In 
addition, they were also shown to impair the strength of the excitatory post synaptic 
potential recorded in these neurons 
32
.  Aβ oligomers also have been linked with neuronal 
damage caused by tau. Recently, Aβ oligomers have also been extracted from the brain of 
AD patients. Using Size Exclusion Chromatography and Immunoprecipitation, dimers of 
Aβ 42 were isolated from Tris Buffered Saline soluble cortical extracts of AD brains. 
These Aβ dimers have been shown to trigger tau hyperphosphorylation and disruption of 
13 
the neuritic cytoskeleton. This effect was reduced when tau expression was knocked 
down with siRNA and exacerbated with overexpression of tau 
33
. Aβ oligomers have 
been shown to require tau in order to impair axonal transport of mitochondria and TrkA 
(Tyrosine Kinase Nerve Growth Factor Receptor) in wild type neurons and reduction in 
tau protects against Aβ induced axonal damage 34. These findings provide a strong link 
between Aβ oligomers and the aggregation of hyperphosphorylation of tau which results 
in its dissociation from microtubules and triggers the formation of neurofibrillary tangles.   
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Figure 1.4 Effect of oligomers on synapses. (A) CHO-APP cell media 
immunoprecipiation with anti-Aβ antibodies (B), (D) Decrease in spine density when 
treated with oligomers (C) Quantification of spine density and length when treated with 
oligomers 
32
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1.3.3  Proteolytic Processing of APP 
The Aβ40 and Aβ42 proteins are formed by sequential cleavage of a larger 
precursor protein, APP (Amyloid precursor protein), by two proteases, β- and γ- 
secretase. APP is a large type 1 transmembrane protein and is expressed in 3 different 
isoforms which contain 695, 751 and 770 residues. APP-751 and APP-770 are 
abundantly expressed in non neuronal cells while APP-695 is expressed abundantly in 
neuronal cells 
1
.  APP is closely related to two other proteins Amyloid Precursor Like 
Protein – 1 (APLP-1) and Amyloid Precursor Like Protein – 2. Although these proteins 
are 60% similar the Aβ regions are not conserved and there are no known mutations that 
cause familial forms of AD 
35
. The physiological role of APP is not very clear. Single 
APP knockout mice are viable but show decreased Long Term Potentiation. These effects 
can be rescued by knocking in the sAPPα gene which shows that the ectodomain of APP 
is sufficient to restore learning and memory related functions. APP expression is 
triggered due to brain injury suggesting that APP might have a role to play in  repair of 
tissue after damage. It has also been suggested that APP might function as a receptor. 
Notch signaling involves cleavage of Notch proteins and it has been suggested that APP 
might also have extracellular ligands that trigger cleavage to turn off its normal functions 
36
.   
Three different proteases affect production of Aβ from the precursor protein APP. 
If APP is cleaved by the enzyme α-secretase, the ectodomain of APP (i.e. the N terminal 
fragment named sAPPα) is released (ectodomain shedding) and an 83 residue long 
COOH fragment is further cleaved via γ-secretase resulting in the formation of a smaller 
16 
p3 fragment (see Fig.1). An alternative pathway involves cleavage by β-secretase, 16 
amino acids N terminal to the α-secretase site which results in the release of a large 
soluble fragment called sAPPβ and a membrane bound fragment C-99.  The sAPPα 
fragment has been shown to be neuroprotective and benefical for adult neurogenesis. 
Further, cleavage of the 99 amino acid carboxy terminal fragment by γ-secretase, results 
in the formation of Aβ42 and Aβ40 and the APP Intracellular Domain (AICD) 
37; 38
 . While 
β-secretase and α-secretase cleavages are lumenal, γ-secretase cleavage occurs within the 
membrane. β-secretase is a membrane bound protease while γ-secretase is a membrane 
embedded complex with a catalytic domain. It is interesting to note that most of the 
genetic mutations in APP that cause early onset of AD are centered around the various 
enzyme cleavage sites on APP. The Swedish mutation that was mentioned earlier, occurs 
at the cleavage site of the β-secretase  enzyme making APP a much better substrate for 
cleavage 
39
. Other mutations occur at the γ-secretase cleavage site on APP. While β-
secretase is a 501 amino acid long protein, γ-secretase is now believed to be a complex of 
proteins called the „Presenilins‟. Presenilin mutations are also known to cause Familial 
forms of AD as well 
40
.APP is believed to be recycled from the cell membranes back into 
sub-cellular compartments 
41
. APP cleavage could therefore occur in multiple locations 
like the secretory pathway or the endosomes 
35
.  The secretases involved in APP cleavage 
are excellent targets for therapeutic development because they are responsible for Aβ 
generation. Controlling APP cleavage and the subsequent synthesis of Aβ interferes with 
the actual disease pathogenesis rather than simply controlling symptoms of the disease. 
Several different strategies are being developed to modulate secretase activity as 
therapeutic strategies for Alzheimer‟s Disease. 
17 
 
 
 
 
Figure 1.5 Proteolytic processing of APP. APP can be processed through the 
amyloidogenic or non-amyloidogenic pathways. The amyloidogenic pathway involves 
luminal cleavage by the enzyme β-secretase, resulting in a large soluble fragment, 
sAPPβ, and a smaller membrane-bound fragment, C-99, which is further cleaved by the 
γ-secretase complex in the membrane. The non-amyloidogenic pathway involves the 
cleavage by α-secretase in the middle of the Aβ sequence, forming sAPPα and a smaller 
C-terminal fragment, C-83. C-83 is further cleaved by the γ-secretase complex to form 
p3. 
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1.4 Antibodies and their Recombinant Formats 
Targeting Aβ or APP cleavage requires reagents that are specific and well 
tolerated. In addition, there is a lack of reliable early diagnostic tools in order enable eary 
identification of the disease. One approach is to use antibodies since they are very 
specific to the antigen that they recognize. Antibodies are a special class of proteins that 
play an important role in maintaining our immunity. These proteins are produced by B-
lymphocytes as part of the humoral immune system. Antibodies like Ig-G 
(Immunoglobulin G) are Y shaped molecules that have heavy and light chains which 
contain either variable or constant regions 
42
.   
Variable regions differ between each antibody and confer the specificity that is 
required. Specific regions within the variable parts called the complementarily 
determining regions or CDR regions have different sequences enabling unique antigen 
binding. The constant region is responsible for effector functions and recruits other 
molecules like complement proteins that elicit an immune response.  An almost limitless 
repertoire of antibodies is generated in the human body from a limited number of 
sequences. This process is called VDJ recombination. The heavy chain regions contain V 
(variable) regions, D (diversity regions) and J (joining) regions that recombine in 
different ways. Similarly, the light chains also have V and D regions that add further to 
the number of possible combinations 
43
. When the immune system develops, antibodies 
that are highly reactive to antigens in the body are eliminated by a phenomenon called 
clonal deletion. The specific region on the antigen that the antibody recognizes is called 
the epitope. The antibody binding may be an induced fit interaction and strong 
19 
interactions have a dissociation constant in the picomolar/ low nanomolar region. Full 
length antibodies like IgG‟s can be raised in hosts like mice against specific antigens for 
therapeutic purposes.   
However, monoclonal antibodies like those raised in mice, pose risks because 
they can lead to host immune reactions when administered to humans. In addition, having 
the constant region may also trigger an immune response. Recombinant antibodies have 
recently risen to become one of the most important classes of antibodies being developed 
as therapeutics 
44
. There are several different formats that recombinant antibodies can 
utilize. If the constant region is removed the remaining part of the antibody structure 
forms an Fab fragment (approximately 55 kD). Single chain variable fragment antibodies 
(scFvs) consist of the variable heavy and light chains of an antibody linked together 
(approximately 28 kD). Variable heavy chains alone are found in some recombinant 
antibodies like Nanobodies (approximately 15 kD). Bispecific antibodies are formed 
when two scFv fragments are combined. ScFv may also be combined to form triabodies 
(trivalent approximately 75 kD) and tetrabodies (tetravalent approximately 100 kD). 
ScFvs are an important class of recombinant antibodies that are smaller, less 
immunogenic since they do not contain the Fc region 
45
 that causes inflammatory 
reactions and can be expressed intracellularly for enhanced localization Recombinant 
antibody fragments have been developed for clinical applications like colorectal cancer 
diagnostics, ovarian, skin and breast cancer therapeutics and Crohn‟s Disease. Several of 
these are currently in different stages of human clinical trial evaluations . Recombinant 
antibodies conjugated with toxins have been used to selectively target tumor cells and kill 
them
46
. Potent receptor mediated killing of targets, low immunogenicity and low 
20 
extracellular toxicity are some of the advantages of using such scFv-toxin fusion proteins 
as therapeutics. Currently, scFv-angiogenin and scFv-cytokine immunotherapies are 
being developed for cancer treatments 
47
. ScFvs have also been isolated against specific 
conformations of amyloid proteins involved in the pathogenesis of Alzheimer‟s disease 
and Parkinson‟s disease and shown to reduce the toxic effects of misfolded proteins in 
human neuronal SHSY-5Y cells 
48
.   
 
 
Figure 1.6 Depiction of various recombinant antibody formats derived from the 
parent IgG molecule. Single chain variable fragment antibodies (scFv), Fab, Bispecific 
antibodies and multivalent antibodies are all recombinant formats being developed for 
therapeutic applications 
44
. 
 
21 
1.5 References 
1. Selkoe, D. J. (2001). Alzheimer's disease: genes, proteins, and therapy. Physiol 
Rev 81, 741-66. 
 
2. Golde, T. E. (2003). Alzheimer disease therapy: can the amyloid cascade be 
halted? J Clin Invest 111, 11-8. 
 
3. (2011). 2011 Alzheimer's disease facts and figures. Alzheimers & Dementia 7, 
208-44. 
 
4. Selkoe, D. (2002). Alzheimer's disease: Conversation with an expert. Harv Health 
Lett 27, 5. 
 
5. Walsh, D. M. & Selkoe, D. J. (2004). Deciphering the molecular basis of memory 
failure in Alzheimer's disease. Neuron 44, 181-93. 
 
6. Selkoe, D. J. & Schenk, D. (2003). Alzheimer's disease: molecular understanding 
predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 43, 545-84. 
 
7. Galasko, D. (2005). Biomarkers for Alzheimer's disease--clinical needs and 
application. J Alzheimers Dis 8, 339-46. 
 
8. Hampel, H., Shen, Y., Walsh, D. M., Aisen, P., Shaw, L. M., Zetterberg, H., 
Trojanowski, J. Q. & Blennow, K. (2010). Biological markers of amyloid beta-
related mechanisms in Alzheimer's disease. Experimental Neurology 223, 334-
346. 
 
9. Selkoe, D. J. (1991). The molecular pathology of Alzheimer's disease. Neuron 6, 
487-98. 
 
10. Selkoe, D. J. (1991). Alzheimer's disease. In the beginning. Nature 354, 432-3. 
 
11. Mandelkow, E. M. & Mandelkow, E. (1998). Tau in Alzheimer's disease. Trends 
Cell Biol 8, 425-7. 
 
12. Mandelkow, E. (1999). Alzheimer's disease. The tangled tale of tau. Nature 402, 
588-9. 
 
22 
13. Greenwald, J. & Riek, R. (2010). Biology of amyloid: structure, function, and 
regulation. Structure 18, 1244-60. 
 
14. Duda, J. E., Lee, V. M. & Trojanowski, J. Q. (2000). Neuropathology of 
synuclein aggregates. J Neurosci Res 61, 121-7. 
15. Bolton, D. C., McKinley, M. P. & Prusiner, S. B. (1982). Identification of a 
protein that purifies with the scrapie prion. Science 218, 1309-11. 
 
16. Lu, Z. Y., Baker, C. A. & Manuelidis, L. (2004). New molecular markers of early 
and progressive CJD brain infection. J Cell Biochem 93, 644-52. 
 
17. Yan, L. M., Velkova, A., Tatarek-Nossol, M., Andreetto, E. & Kapurniotu, A. 
(2007). IAPP mimic blocks Aβ cytotoxic self-assembly: cross-suppression of 
amyloid toxicity of Aβ and IAPP suggests a molecular link between Alzheimer's 
disease and type II diabetes. Angew Chem Int Ed Engl 46, 1246-52. 
 
18. Haass, C. & Selkoe, D. J. (1998). Alzheimer's disease. A technical KO of 
amyloid-beta peptide. Nature 391, 339-40. 
 
19. Conway, K. A., Baxter, E. W., Felsenstein, K. M. & Reitz, A. B. (2003). 
Emerging beta-amyloid therapies for the treatment of Alzheimer's disease. Curr 
Pharm Des 9, 427-47. 
 
20. Schneider, L. S., Insel, P. S. & Weiner, M. W. (2011). Treatment with 
cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease 
Neuroimaging Initiative. Arch Neurol 68, 58-66. 
 
21. Citron, M. (2010). Alzheimer's disease: strategies for disease modification. Nat 
Rev Drug Discov 9, 387-98. 
 
22. Weiner, H. L. & Frenkel, D. (2006). Immunology and immunotherapy of 
Alzheimer's disease. Nat Rev Immunol 6, 404-16. 
 
23. Hardy, J. A. & Higgins, G. A. (1992). Alzheimer's disease: the amyloid cascade 
hypothesis. Science 256, 184-5. 
 
24. Pangalos, M. N., Jacobsen, S. J. & Reinhart, P. H. (2005). Disease modifying 
strategies for the treatment of Alzheimer's disease targeted at modulating levels of 
the beta-amyloid peptide. Biochem Soc Trans 33, 553-8. 
23 
25. Walsh, D. M. & Selkoe, D. J. (2007). A beta oligomers - a decade of discovery. J 
Neurochem 101, 1172-84. 
 
26. Selkoe, D. J. (2008). Soluble oligomers of the amyloid beta-protein impair 
synaptic plasticity and behavior. Behav Brain Res 192, 106-13. 
 
27. Lesne, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., 
Gallagher, M. & Ashe, K. H. (2006). A specific amyloid-beta protein assembly in 
the brain impairs memory. Nature 440, 352-7. 
 
28. Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., 
Krafft, G. A. & Klein, W. L. (2003). Alzheimer's disease-affected brain: presence 
of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible 
memory loss. Proc Natl Acad Sci U S A 100, 10417-22. 
29. Zameer, A., Kasturirangan, S., Emadi, S., Nimmagadda, S. V. & Sierks, M. R. 
(2008). Anti-oligomeric Aβ single-chain variable domain antibody blocks Aβ-
induced toxicity against human neuroblastoma cells. J Mol Biol 384, 917-28. 
 
30. Jan, A., Hartley, D. M. & Lashuel, H. A. (2010). Preparation and characterization 
of toxic Aβ aggregates for structural and functional studies in Alzheimer's disease 
research. Nat Protoc 5, 1186-209. 
 
31. Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. 
S., Rowan, M. J. & Selkoe, D. J. (2002). Naturally secreted oligomers of amyloid 
beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 
416, 535-9. 
 
32. Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J. & 
Sabatini, B. L. (2007). Natural oligomers of the Alzheimer amyloid-beta protein 
induce reversible synapse loss by modulating an NMDA-type glutamate receptor-
dependent signaling pathway. J Neurosci 27, 2866-75. 
 
33. Jin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D. & Selkoe, D. J. (2011). 
Soluble amyloid {beta}-protein dimers isolated from Alzheimer cortex directly 
induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci 
U S A. 
 
34. Vossel, K. A., Zhang, K., Brodbeck, J., Daub, A. C., Sharma, P., Finkbeiner, S., 
Cui, B. & Mucke, L. (2010). Tau reduction prevents Aβ-induced defects in axonal 
transport. Science 330, 198. 
24 
 
35. Vetrivel, K. S. & Thinakaran, G. (2006). Amyloidogenic processing of beta-
amyloid precursor protein in intracellular compartments. Neurology 66, S69-73. 
 
36. Wolfe, M. S. & Guenette, S. Y. (2007). APP at a glance. J Cell Sci 120, 3157-61. 
 
37. Wilquet, V. & De Strooper, B. (2004). Amyloid-beta precursor protein processing 
in neurodegeneration. Curr Opin Neurobiol 14, 582-8. 
 
38. Selkoe, D. J. (1999). Translating cell biology into therapeutic advances in 
Alzheimer's disease. Nature 399, A23-31. 
 
39. Haass, C., Lemere, C. A., Capell, A., Citron, M., Seubert, P., Schenk, D., 
Lannfelt, L. & Selkoe, D. J. (1995). The Swedish mutation causes early-onset 
Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Nat 
Med 1, 1291-6. 
 
40. Woo, H. N., Baik, S. H., Park, J. S., Gwon, A. R., Yang, S., Yun, Y. K. & Jo, D. 
G. (2011). Secretases as therapeutic targets for Alzheimer's disease. Biochem 
Biophys Res Commun 404, 10-5. 
 
41. Citron, M., Eckman, C. B., Diehl, T. S., Corcoran, C., Ostaszewski, B. L., Xia, 
W., Levesque, G., St George Hyslop, P., Younkin, S. G. & Selkoe, D. J. (1998). 
Additive effects of PS1 and APP mutations on secretion of the 42-residue amyloid 
beta-protein. Neurobiol Dis 5, 107-16. 
42. Holliger, P. & Bohlen, H. (1999). Engineering antibodies for the clinic. Cancer 
Metastasis Rev 18, 411-9. 
 
43. Market, E. & Papavasiliou, F. N. (2003). V(D)J recombination and the evolution 
of the adaptive immune system. PLoS Biol 1, E16. 
 
44. Holliger, P. & Hudson, P. J. (2005). Engineered antibody fragments and the rise 
of single domains. Nat Biotechnol 23, 1126-36. 
 
45. Miller, T. W. & Messer, A. (2005). Intrabody applications in neurological 
disorders: progress and future prospects. Mol Ther 12, 394-401. 
46. Cao, Y., Marks, J. D., Marks, J. W., Cheung, L. H., Kim, S. & Rosenblum, M. G. 
(2009). Construction and characterization of novel, recombinant immunotoxins 
targeting the Her2/neu oncogene product: in vitro and in vivo studies. Cancer Res 
69, 8987-95. 
25 
 
47. Holliger, P., Manzke, O., Span, M., Hawkins, R., Fleischmann, B., Qinghua, L., 
Wolf, J., Diehl, V., Cochet, O., Winter, G. & Bohlen, H. (1999). 
Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma 
induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA 
bispecific fusion proteins. Cancer Res 59, 2909-16. 
 
48. Emadi, S., Kasturirangan, S., Wang, M. S., Schulz, P. & Sierks, M. R. (2009). 
Detecting morphologically distinct oligomeric forms of alpha-synuclein. J Biol 
Chem 284, 11048-58. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
26 
CHAPTER 2 
Technical Background 
2.1 β-secretase or BACE-1 as a drug target in AD   
The enzyme that cleaves APP in the amyloidogenic pathway resulting in the 
formation of abeta is called β-secretase. Beta secretase is a 501 amino acid long protein. 
It is expressed in different types of cells with neurons being one of the highest expressers. 
The Aβ sequence begins at the β -secretase cleavage site on APP. The Swedish mutation 
(one of the causes for Familial forms of AD) occurs at the beta-secretase cleavage site 
resulting in a replacement of Methionine with Leucine making APP a better substrate for 
β-secretase cleavage 1. This mutation makes APP a 50 times better substrate for cleavage 
by the β-secretase enzyme and makes 6-8 times higher concentrations of abeta resulting 
in early onset of Alzheimer‟s Disease.  
Several different groups simultaneously tried to clone and characterize the 
enzymes that may function as the β-secretase enzyme that cleaves APP. β-site APP 
cleaving enzyme (BACE-1) was shown to be one of two beta-secretase enzymes and also 
the major enzyme to cleave APP. Soon after BACE-1 was discovered, another enzyme 
with 64% similarity was also shown to cleave APP and this was called BACE-2. BACE-2 
expression is extremely low in the brain and neuronal tissue 
2
. BACE-1 cleavage is 
luminal and is optimum at acidic pH ~ 4.5. BACE-1 is synthesized in the Endoplasmic 
Reticulum with a prodomain which is cleaved in the Golgi 
3
. The maturation of BACE-1 
makes it a much better enzyme. BACE-1 is found mostly in the Trans Golgi Network, the 
secretory pathway and in the endosomes while very low levels of BACE-1 have been 
27 
detected in the lysosomes. BACE-1 is an aspartyl protease. It has two aspartate residues 
in its catalytic site and functions as a dimer.   
The mechanism of cleavage involves removal of a proton from the water 
molecule by one of the aspartate. This leads to the formation of an intermediate which 
ultimately rearranges to form the amide resulting in cleavage 
4
. BACE-1 is recycled from 
its sub cellular locations to the cell surface and back. Also, it has a unique transmembrane 
domain amongst other aspartyl proteases which is believed to result in increased retention 
of this enzyme in the late Golgi and the Trans Golgi network. Increased localization in 
the ER has been shown to reduce generation of abeta while increased targeting towards 
acidic compartments increases abeta generation 
5
. Reducing levels of GGA3, which is a 
caspase-3 substrate, results in increased localization of BACE-1 to the acidic 
compartments of the cell resulting in an increase in APP cleavage. It has been previously 
shown that GGA3 levels are decreased in the brains of AD patients where neuronal 
apoptosis occurs 
6
. 
It is also believed that BACE-1 might interact with lipid rafts. Lipid rafts are 
microdomains in the plasma membrane that are relatively tightly packed with 
glycoproteins, signaling molecules and rich in cholesterol 
7. Aβ has also been shown to 
co-localize with lipid raft markers like Flotillin and Caveolin. Cholesterol has been 
shown to increase the risk of having AD. Higher cholesterol might give rise to bigger 
lipid rafts and thus may facilitate BACE-1 cleavage of APP by bringing them closer.  
In order to confirm that BACE-1 is the major enzyme that cleaves APP and to 
study if BACE-1 had any other functions in-vivo, BACE-1 knockout mice were 
28 
developed. BACE -/- mice appeared to be normal and also had normal morphology, 
hematology, blood and urine chemistries when compared with control BACE +/+ mice. 
Since BACE-1 is considered to be a rate limiting step in Aβ synthesis, it has become one 
of the most important targets for drug development. Several drug companies are currently 
testing inhibitors developed based on the structure of the catalytic site of BACE-1. All of 
these inhibitors are targeted towards affecting the activity of the enzyme by interfering 
with the catalytic site. One of the most potent inhibitors was OM-992 with a Ki of 1.6 
nM. Most of these inhibitors are much less efficient in cell systems since they have 
permeability issues. Moreover, careful analysis of knockout mice showed that BACE-1 
deficiency results in hypomyelination 
8
.  
Further research showed that BACE-1 also cleaves several other physiologically 
important substrates in addition to neuregulin or NRG-1 which is involved in myelin 
formation like α2,6-sialyltransferase and the beta sub-unit of Voltage gated sodium 
channels 
5
. All of the known substrates for BACE-1 are membrane bound substrates like 
APP. Some of the other substrates that BACE-1 cleaves are P-selectin glycoprotein 
ligand-1 (PSLG-1) , Amyloid precursor like proteins (APLP-1 and APLP-2) and the Low 
density Lipoprotein related receptor Protein (LRP) 
9; 10
. The beta-2 sub unit of voltage 
gated sodium channels seems to be a major substrate of this enzyme in the brain. 
Impaired sodium channel function leads to tremors, ataxia and behaviorial phenotypes 
that were observed in BACE-1 knockout mice 
11
.  
This suggests that BACE-1 might play an important role in normal physiological 
functioning of the central nervous system. The discovery of these important substrates 
29 
has now led us to question the strategy of targeting the catalytic site of the enzyme. A 
superior strategy might be to block the activity of BACE-1 specifically towards APP 
preventing BACE-1 from accessing its cleavage site on APP. This will not potentially 
affect the catalytic site of BACE-1 thereby leaving BACE-1 intact to cleave the other 
physiologically important susbtrates. This therapeutic is likely to be more specific since it 
will potentially target only APP cleavage and not impair cleavage of the other substrates 
thus reducing the possibility of unwanted side effects due to blanket inhibition of the 
enzyme.  
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Figure 2.1 Representation of BACE-1 localization and the different substrates that 
it cleaves under normal physiological conditions 
7
. 
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Figure 2.2 Possible role of lipid rafts in Alzheimer‟s Disease. Increase in 
cholesterol levels due to different reasons might result bringing the domains of the lipid 
rafts together thus enabling interaction between BACE-1 and APP resulting in increased 
levels of abeta generation. These are present in all the locations where BACE-1 is 
normally found 
12
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2.2 Recombinant Antibody Display  
The original method used to produce antibodies was to inject mice with the 
relevant antigen and isolate antibodies generated in the immune response. The spleen 
cells of the animal are then fused with cancer cells to generate hybridomas that can be 
screened to isolate single clones and produce monoclonal antibodies. However, murine 
antibodies may cause immune reactions and are very cumbersome to produce since they 
involve animal maintenance and handling 
13
. Human anti-mouse antibodies have been 
reported in several cases as in immune reaction against monoclonal antibodies generated 
in mice. Attempts are being made to try and modify the scaffold regions of antibodies in 
order to “humamize” them for therapeutic functions 14. In addition, monoclonal 
antibodies being used for immunotherapy mostly contain the Fc region of the IgG 
antibody which is responsible for triggering an immune response. Recombinant 
antibodies like single chain variable fragment antibodies (scFv) may be potentially safer 
options since they lack the Fc region. Using antibody sequences derived from human 
blood samples, genetic engineering has enabled the “display” of these proteins on the 
surface of viruses and yeast in recombinant formats. This eliminates the necessity to 
produce antibodies in mice. Instead, the entire process of selection and screening is 
performed in-vitro 
15
.  
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2.2.1 Phage Display 
Phage display involves the genetic modification of bacteriophage(a virus) in order 
to express scFv in fusion with their gIII coat protein. This particular type of phage which 
is called M13 is a filamentous phage that replicates in hosts without destroying the host 
cells 
16
. The phage carry a single strand DNA which encodes the scFv in fusion with the 
coat protein and the synthesis of this protein along with scFv occurs before phage 
particles are released. The scFv retain their properties like specificity and ability to bind 
and recognize their antigen 
17
. Hence, they can be used for assays performed with the 
antigen and scFv in solution as if there weren‟t any phage being present in solution. For 
example, phage expressing scFv on their surface are used to select for antibodies that 
bind specific antigens using in-vitro assays like ELISAs 
18
. Antibody libraries with 
diversities upto 10
10
 have been reported for phage libraries. The process of identifying the 
scFv that binds to a particular antigen is called “panning”. It involves incubation with the 
immobilized antigen in order to wash away the non-binders and repeat the process in 
order to enrich the positive pool of phage. After several such rounds of panning, clones 
are screened individually in order to obtain monoclonal antibodies 
19
.  
2.2.2 Yeast Display 
More recently, yeast display has been developed as yet another method of 
recombinant antibody display. Unlike phage which only display one copy per clone, 
several thousand copies of the scFv are displayed in fusion with the agglutinin receptor 
which is expressed on the yeast surface and modulates adhesion and cell-cell interactions. 
34 
Libraries constructed with diverse genetic sequences have been displayed on 
Saccharomyces Cerevisiae with upto 10
9
 diversity 
20
. Diversity in the library arises from 
either the mutations in the hypervariable  Complimentarity determining regions (CDR) of 
heavy and light chains and also the random association of heavy and light chain during 
cloning and transformations. Introducing mutations in the CDR regions is also used to 
construct second generation libraries in order to select for clones with improved affinity 
(Affinity maturation) 
21
. The insert is cloned into the pYD1 vector and the expression of 
scFv fused with agglutinin is under the regulation of the Gal1 promoter. This is triggered 
by adding Galactose in the media. Scfv expression is very tightly regulated and helps in 
effective library propogation. When these scFv sequences are obtained without 
immunization, this method of display is termed non-immune yeast display.  
Every scFv is fused with c-myc and HA tag proteins which enables labeling and 
detection. Yeast display offers several advantages over the earlier technology namely 
phage display. Choosing a eukaryotic system ensures proper folding and post-
translational modification which ensures that the functionality in antibodies is 
maintained. Expression bias is minimized and the observed diversity is almost equal to 
the diversity in DNA sequences. In addition, yeast display several 1000 copies of the 
scFv on their surface unlike the phage 
21
. Another great strength of this technique is that 
yeast uses Fluoroscence Activated Cell Sorting to select for single clones based on 
affinity. After inducing expression of scFv, yeast are initially incubated with biotinylated 
antigen and streptavidin coated magnetic beads and passed through a magnetic field. The 
non-binders are washed away and antigen binders are plunged out and this process is 
repeated to enrich for antigen binders 
22
. This technique is called Magnetic-activated Cell 
35 
Sorting. After several rounds of magnetic bead based enrichment, yeast expressing scFv 
are double labeled with anti-cmyc antibody and Goat-anti mouse secondary antibody that 
is conjugated with a fluorophore (Fluoroscein Isothyocyanate or FITC) and antigen 
followed by strepatividin conjugated with a fluorophore (Phycoerythrin or PE) 
20
. This 
enables detection of scFv expression using the c-myc tag and picking double positive 
yeast i.e clones that express scFv and that bind the antigen of interest. FACS sorting 
enables quantitative isolation of clones binding a particular antigen. Using FACS 
labeling, the mean value of fluorescence intensity at different antigen concentrations can 
be used to estimate the Kd value for the antibodies. Using FACS for affinity maturation, 
upto million fold increase in affinity of scFv have been reported 
23
.  
The ScFv obtained from screening using FACS can further be cloned into a 
soluble expression system that enables secretion and purification of scFv from the 
supernatant. This process involves the use of homologous recombination. The scFv is 
secreted with a 6-His tag which can be used for purification using Immobilized metal 
affinity chromatography (IMAC). Further, the presence of the v5 tag enables detection of 
scFv after soluble expression 
24
. 
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Figure 2.3 Schematic of AFM based panning for antigen specific binders from a 
phage display library. 
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Figure 2.4 Concept of the yeast display library which expresses scFv in fusion 
with the agglutinin receptor that is tightly regulated by the Gal1 promoter
16
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2.3 Immunotherapy for AD 
2.3.1 Immunotherapy against Aβ 
Immunotherapy has been used to successfully treat several diseases. Active 
immunotherapy involves recruitment of the host immune system to target a specific 
protein or marker involved in the disease while Passive immunotherapy involves the 
administration of antibodies to the host in order to provide immunity. This has been very 
successful in treating several pathogenic diseases that can lead to severe but self limiting 
illnesses. Edward Jenner‟s discovery that cowpox infection resulted in immunity against 
small pox, led to the discovery of vaccines. Active immunotherapy can also involve 
increasing activity of Antigen Presenting Cells like Dendritic cells and increase activation 
of T-cells in order to recruit the immune system. This has resulted in the eradication of 
small pox. Today, vaccination is effective in controlling several similar diseases like 
Diphtheria, Polio, Plague, Rabies, Measles and so on. However, we still need effective 
active immunotherapy for chronic diseases like cancer 
25
.  
Antibodies are becoming a very important class of therapeutics. The concept of 
monoclonal antibodies was first developed by Kohler and Milstein. These were produced 
in mice by fusing the spleen of the immunized mouse with hybridomas in order to enable 
stable production of the antibodies. Monoclonal antibodies are one of the most popular 
formats of passive immunotherapy. In addition, they can also be used as diagnostics 
when raised against biomarkers and when raised against some early biomarkers, these 
diagnostic tools could be of incredible value 
14
. Antibodies have been raised against 
specific antigens like the Carcinoembryonic antigen (CEA) and the Epidermal Growth 
39 
Factor (EGFR) which are over expressed in cancers like colon cancer and breast cancer. 
Similar approaches have resulted in therapeutics like Rituximab for Non-Hodgkin‟s 
Lymphoma and Zenapax which reduces allograft reduction both is being approved by the 
FDA 
26
. After the discovery of the proteins and pathways involved in the development of 
AD, considerable interest was generated in the application of immunotherapy towards 
treatment of AD. Active immunization with Aβ in mice resulted in the generation of a 
robust immune response against the Aβ protein. Antibodies against the N-terminal were 
previously shown to decrease Aβ levels and specifically fibril formation in cells 27. Mice 
were administered either the entire protein or parts of the Aβ protein using intranasal 
delivery along with an adjuvant. Active immunization resulted in a reduced accumulation 
of Aβ pathology in mice and decline in loss of cognition. Similar results were also 
obtained from active immunization using Aβ fibrils 28.  
Based on the results observed in mice, Elan Pharmaceuticals proceeded to initiate 
clinical trials with a synthetic Aβ peptide called AN1792. No side effects were observed 
in the Phase I trial which had positive outcomes. However the Phase II trial had to be 
aborted since 6 % of the patients developed meningeoencephalitis 
29
. This inflammation 
was caused because of the recruitment of T-cells to the brain as observed in one of the 
post mortem brains. The vaccine succeeded in targeting Aβ in the brain and recruiting the 
immune system. Some of the patients that did show an increase in antibody titers also 
showed a slower rate of cognitive decline but overall, there was no significant decrease in 
loss of cognition in comparison with the placebo 
30
. Several monoclonal antibodies 
(10D5, 3D6, m266) were raised against Aβ and administered to mice. Passive 
administration of these antibodies also resulted in a reduction in Aβ levels in mice brains 
40 
31
. A small percentage of antibodies enters the brain and activated microglia in the brain 
to initiate clearance. One of the methods of Aβ clearance is believed to occur through the 
Peripheral Sink Hypothesis. This also resulted in a decrease in cognitive decline and 
interestingly affected the levels of tau 
32
. These experiments were conducted in triple 
transgenic mice i.e mice that express mutations for the APP, PS1 and Tau proteins. Triple 
transgenic mice develop Amyloid fibrils and neurofibrillary tangles and this enables the 
monitoring of the effect of therapeutics on plaque formation as well as tangles.   
2.3.2 Conformation specific antibodies 
 Owing to the unsafe reactions observed in earlier clinical trials, several new 
strategies are being applied to develop immunotherapies for Alzheimer‟s Disease. 
Previous efforts focused on targeting Aβ in general. Some such studies reported a 
decrease in cognitive decline without a corresponding decrease in the number of plaques. 
This might be explained by a possible effect on soluble aggregates of Aβ 33. We now 
know that soluble oligomer aggregates of Aβ are toxic to neurons and can inhibit Long 
Term Potentiation. Hence antibodies that target the toxic species might be of significant 
therapeutic value. Several groups reported the generation of monoclonal antibodies 
against Aβ oligomers. Charles Glabe describes the classification of Aβ oligomers  
immunologically into 2 classes namely prefibrillar and fibrillar oligomers further 
showing that they are identified by either one of the oligomer specific antibodies A11 and 
OC-1 
34
.  
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Lambert et al injected rats with a mixture of Aβ monomers and ADDL oligomers 
to obtain toxicity neutralizing antibodies specific towards ADDL oligomers. Lambert et 
al also reported that they raised NU-2 and NU-4, 2 monoclonal antibodies that recognized 
ADDLs (Aβ oligomers) and specifically recognized AD brain tissue. Oxidative stress is 
an important feature of AD 
35
. Often, measuring levels of Reactive Oxygen Species 
(ROS) is used as a tool to compare the extent of oxidative damage in cells in the presence 
of toxic species like Aβ oligomers. Addition of NU-2 and NU-4 antibodies also decreased 
Reactive Oxygen Species generation in cells incubated with ADDLs 
36
. However, 
monoclonal antibodies still contain the constant Fc region which is responsible for 
recruiting the immune system. Moreover, monoclonal antibodies being produced in mice 
may elicit human anti-mouse immune reactions (HAMA).  
2.3.3 Recombinant Antibody based Immunotherapy against Aβ 
Single chain variable fragment or similar recombinant antibody based 
therapeutics hold great promise to develop a safer and effective therapeutic for 
Alzheimer‟s disease. Manoutcharian et al were successful in developing Aβ binding 
recombinant antibodies. These were selected from scFv libraries constructed from the 
spleen of mice immunized with Aβ42 37. Recombinant antibodies were also generated by 
immunizing mice with phage displaying the N-terminal of Aβ. Mice produced antibodies 
that recognized coat proteins on the phage as well as the Aβ protein 38. Recent research 
has focused on isolation of recombinant antibodies against specific conformations of Aβ.  
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Liu et al., isolated scFv against a specific region of Aβ 17-28 which is hydrophobic. The  
scFv reduced toxic effects of Aβ aggregates towards an SHSY-5Y neruoblastoma cell 
line 
39
.  
This procedure of immunization resulted in long lasting immune response.  
Zameer et al., isolated recombinant single chain antibodies against Aβ oligomer species 
from a naïve phage display library. Using AFM, they isolated scFv A4 and E1 to 
recognize larger oligomers and early stage smaller oligomers but not monomers or fibril 
forms of Aβ. The scFv were also successful in inhibiting fibril formation as characterized 
by Thioflavin staining. Further, these scFv preferentially stained AD brain tissue in a 
mixture of post mortem brain tissue samples from AD and PD patients and age matched 
controls 
40; 41
.  
Several other strategies have been used to develop conformation specific 
antibodies and test them in in-vitro and in-vivo cell models. Meli et al used a yeast two 
hybrid screening system to isolate several scFv against Aβ oligomers. Most of the clones 
recognized the N-terminal of Aβ and were also successful in staining human AD brain 
tissue. In addition, these were also able to inhibit the toxic effect of Aβ oligomers in 
neuronal cell models 
42
. Robert et al. generated recombinant Fab and scFv fragments 
from a monoclonal antibody WO-2 targeting the N-terminal of Aβ. All recombinant 
antibodies selected from a range of mutants had an affinity less than 10 nM and were 
successful in inhibiting fibril formation like the parent monoclonal antibody. In addition, 
these recombinant fragments were also successful in inhibiting the toxic effects of Aβ 
oligomers in neuronal cells 
43
.  
43 
Several studies have also tested passive immunotherapy in mouse models. 
Fukuchi et al used a recombinant scFv antibody against Aβ and used an Adeno associated 
virus to deliver the gene in corticohippocampal regions of AD mouse models. The scFv 
expression was stable and after 6 months, a decrease in amyloid deposits was observed in 
Tg2576 mouse models 
44; 45
. Levites et al tested 3 different scFv developed against N-
terminus of Aβ, C-terminus of Aβ40 and C-terminus of Aβ42. These scFv were 
intracranially injected in mice and 25-50% reduction in Aβ deposits was observed 46.  
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Figure 2.5 AD brain slices showing reduction in plaques in the case of scFv 
treatment in comparison with control brain slices. Levels of abeta with scFv treatment 
showing decrease in comparison with controls abeta levels. 
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2.4 Recent clinical trials in targeting secretases  
Recent strategies to develop therapeutics for Alzheimer‟s disease also include 
targeting the proteolytic pathway leading to Aβ generation. These include inhibitors that 
are targeted towards BACE-1 or beta secretase and gamma secretase. Both enzymes 
cleave APP sequentially and hence inhibition of these enzymes will result in reduced 
production of Aβ. Several structure based inhibitors were developed against beta-
secretase since initial experiments with BACE-1 knockout mice showed normal 
phenotypes 
7
. However, we now know that BACE-1 has other physiological functions 
questioning this strategy.     
 γ-secretase is a complex of 5 different proteins including presenilin which is 
involved in the cleavage process. Presenilin mutations are also implicated in the early 
development of AD. Gamma secretase cleaves within the membrane unlike BACE-1 
cleavage 
47
. However, it also cleaves the Notch signaling protein which is involved in the 
signaling process crucial for neuronal development, cardiac functions, angiogenesis and 
immune system functions. Hence, several questions have been raised about possible 
toxicity issues from non specific inhibition of gamma secretase activity. Blocking Notch 
signaling could increase risks of cancer development 
48
. Eli Lilly recently halted Phase 3 
clinical trials based on a gamma secretase inhibitor shown to reduce Aβ levels in mice 
models. The clinical trials showed that gamma secretase inhibition increased the risk of 
skin cancer 
49
. Currently substrate specific gamma secretase inhibitors are being 
developed. The lack of specificity of several drugs in clinical trials could increase 
possible risk of side effects because of interactions with other random proteins. 
46 
Greengard et al recently reported the discovery of the gamma-secretase activating protein 
GSAP which selectively activates gamma secretase cleavage of APP increasing Aβ levels 
alone 
50
. GSAP might be a much safer target from a therapeutic stand point. Lack of 
specificity in several of these strategies is a major concern of using small molecule based 
therapies.   
 
 
Figure 2.6 Gamma secretase complex: Psn might form a low molecular weight 
complex which is degraded or a high molecular weight complex which leads to the 
formation of the gamma secretase complex 
51
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2.5 Bispecific Antibodies 
One of the recombinant formats of antibodies includes bispecific antibodies. 
Recombinant Bispecific antibodies are a unique class of antibodies since they can be used 
to simultaneously target two identical or different antigens. One of the formats could 
consist of two scFv fragments linked together in one of the two ways as shown below. In 
the case when the two scFv are linked together with an intermediate linker, the construct 
obtained is a tandem scFv. On the other hand, Diabodies are produced by reducing the 
linker size between scFvs in order to enable dimerization and cross over 
52; 53
. Both of 
these formats are represented in Fig 7. Several bispecific antibodies derived from IgG 
formats have also been developed for clinical applications.  These recombinant antibodies 
have been developed to target effector functions to tumor cells in order to treat various 
types of cancers. For example, an scFv against the Carcinoembryonic Antigen (CEA) 
which is widely overexpressed in several types of cancers and a neutralizing scFv were 
cloned into a recombinant bispecific antibody in order to selectively killed tumor cells 
54
. 
Bispecific intrabodies have also been developed successfully to target two different 
receptors in cells 
55
. Table 1.2 has several other examples of bispecific antibodies in 
different formats. 
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Figure 2.7 Various formats in which recombinant antibodies like bispecific 
antibodies and tetrabodies can be constructed 
52
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Table 2.1  
Different formats of bispecific antibodies in clinical trials 
Serial 
No. 
Bispecific 
antibody 
Format Target and Disease application 
1. Catumaxomab, 
phase 2-3 
IgG (mouse/rat) EPCAM x CD3 (ovarian, gastric cancer, 
malignant aescites) 
2. Ertumaxomab, 
phase 2 
IgG (mouse/rat) HER2 x CD3 Metastatic breast cancer 
3. Blinatumomab, 
phase 1 
Tandem scFv C19 x CD3  Non Hodgkins Lymphoma, 
Acute Lymphoblastic Leukemia 
4. MM-111, 
phase 1-2 
(scFv)2HSA 
HAS – human 
serum albumin 
HER2 x HER3 Breast Cancer 
5. rM28, phase 1 Tandem scFv HMW-MAA xCD28 Malignant 
melanoma (High molecular wt 
melanoma assoc. antigen) 
6. MDX-447, 
phase 1 
F(ab)2 humanised EGFR x CD64 Brain and CNS tumors  
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Most bispecific antibodies have been developed for cancer therapeutic 
applications. The therapeutics target a specific antigen over expressed by cancer cells and 
an antigen on T-cells.  This results in activation of a T-cell response selectively against 
cancer cells. CEA, EGFR (Epidermal growth factor receptor) and HER (human 
epidermal growth factor) are antigens over expressed by solid tumors 
56
. Bispecific 
Diabodies and scFv- diabodies have also been developed to treat different types of 
cancers 
55
. For example, diabodies targeting PSMA (Prostate cancer marker) x CD3 have 
shown to trigger T-cell responses and kill human prostate cancer cells in-vitro 
57
. 
Bispecific antibodies are an attractive format to simultaneously target the amyloidogenic 
pathway while increasing APP cleavage via the non-amyloidogenic pathway. A truly 
novel therapeutic would be one that simultaneously enhances α-secretase cleavage 
through the non- amyloidogenic pathway while blocking BACE-1 cleavage through the 
amyloidogenic pathway thus potentially finding an alternate route to APP cleavage in AD 
brains.  
Pharmacokinetics is a major issue associated with bispecific antibodies 
constructed from single chain antibodies. Since the size of these antibodies is usually 50-
60 kD, they are cleared rapidly by the renal systems with a very short half life of about 30 
min. Several modification are usually made to ensure longer half lives in-vivo. 
PEGylation of antibodies has been used as a strategy to increase the stability of single 
chain antibodies 
52
.  
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2.6 Cellular Pathways Involved in Alzheimer’s Disease 
2.6.1 Oxidative stress in Alzheimer’s Disease   
Oxidative stress is a very important phenomenon observed in Alzheimer‟s 
Disease. Mutations at the BACE-1 and gamma-secretase site result in increased 
deposition of Aβ and are found in Familial cases of AD. Such brains also show an 
increase in oxidative stress levels 
58
. Mice expressing APP with the PS1 mutation also 
show antioxidative enzyme activity. Previous work has shown that cells over expressing 
APP bearing Swedish mutations or PS1 mutations become more susceptible to damage 
by oxidative stress like exposure to hydrogen peroxide. Oxidative stress due to ROS can 
also result in activation of the c-Jun N-terminal kinase (JNK) and p38 triggering a 
cascade of signaling events ultimately leading to neuronal apoptosis 
59
.  Post mortem 
tissue analysis has shown the involvement of Caspase enzymes in Sporadic cases of AD. 
Studies have shown that Caspase-3, Caspase-8 and caspase -9 activation is observed 
when cells are stressed by exposure to peroxide. Mitochondria are very susceptible to 
oxidative stress. Overexpression of APP in neuronal cells also results in reduction in 
mitochondrial potential and release in cytochrome-C 
60; 61
. Eckert et al used PC12 cells as 
a model to study oxidative stress related neuronal damage. While both wild type APP and 
Swedish APP resulted in an increase in caspase-3 activity, only Swedish APP expressing 
cells showed an increase in Caspase-2 activity. In the intrinsic pathway for apoptosis, 
Caspase-2 is activated earlier to mitochondrial damage showing that the increase in Aβ  
52 
levels results in activation of the intrinsic pathway. Using a JNK specific inhibitor, they 
were also able to attenuate the caspase activity and mitochondrial damage observed in the 
Swedish APP expressing cells 
59
. 
 
 
Figure 2.8 Schematic showing different steps in the intrinsic and extrinsic 
pathways of apoptosis possibly due to increased levels of aggregate forms of abeta. 
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2.6.2 PKC dependent α-secretase activation  
Protein Kinase C (PKC) signaling is one of the several signal cascade pathways 
used by neuronal cells to respond to environmental changes. PKC is a serine/threonine 
family of proteins that are important for neurotransmitter expression, receptor regulation, 
cell proliferation and synaptic remodeling. PKC molecular cascades are believed to play 
a role in remodeling synapses which is essential in building long term memory 
62
. PKC 
has been previously implicated in the direct modulation of the non amyloidogenic APP 
proteolysis pathway resulting in increased α-secretase cleavage of APP 63. PKC is 
normally found as an inactive form when it is folded into a hairpin structure. In order for 
PKC signaling to happen effectively, 3 consecutive events need to occur. The first step is 
phosphorylation followed by pseudo-substrate exposure and sub-cellular localization. 
Calcium is one of the important activators of PKC.  APP metabolism through the alpha-
secretase pathway is believed to be majorly dependent.  
Several studies have shown that stimulating PKC activity in cell models can 
improve APP cleavage by alpha-secretase. It has also been shown that AD brains are not 
deficient in PKC but actually have reduced or faulty PKC activity.  In mice over 
expressing APP and APP/PS1 transgenes, Etcheberrygaray et al showed that activating 
PKC using benzolactam and bryostatin results in reduced Aβ levels and improves 
behavioral functions. Aβ itself might also react with PKC resulting in reduced 
translocation of active PKC in neuronal cell models as shown by Lee et al 
64
. However, 
Aβ does not affect the expression of PKC. Activation of alpha-secretase results in 
increased levels of the soluble ectodomain fragment of APP sAPPα which has been 
54 
shown to have neuroprotective effects in cell models 
65
. Neuroprotection through PKC 
activation has been shown to be related with the Bcl family of proteins known to be 
involved in cell survival. Increased activation of PKCα also results in increased 
phyosphorylation of Bcl-2 which is known to have anti-apoptotic functions. PKC might 
represent an important cellular pathway that can be used to characterize the modulation 
of secretase pathways in APP processing 
66
. 
 
 
 
 
Figure 2.9 Structure of inactive and active forms of Protein Kinase-C which has 
several important functions including a role in synaptic plasticity and memory 
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CHAPTER 3  
Research Hypothesis 
BACE-1 cleavage of APP is one of the most important steps involved in the 
generation of Aβ which in turn plays a pivotal role in the early pathogenesis of 
Alzheimer‟s Disease. This is one of the most crucial targets for therapeutic development. 
Current attempts to develop BACE-1 based therapeutics target the catalytic site of the 
enzyme. Since previous research has elucidated that BACE-1 has other physiologically 
important substrates, we rationalized that a superior therapeutic strategy for BACE-1 
inhibition specifically would be blocking BACE-1 binding to the APP cleavage site. 
Using antibodies against the BACE-1 site on APP is a very effective strategy since it 
would exploit the high specificity that antibodies have, for the antigen. Also, since the N-
terminal of Aβ begins at the BACE-1 cleavage site, an ideal inhibitor would function 
without cross reacting with the N-terminal of Aβ which is considered to be an 
immunodominant epitope. This is essential in order to develop a specific therapeutic that 
will be effective in inhibiting BACE-1 activity. Further, stimulating the non 
amyloidogenic pathway would ensure APP cleavage happens through an alternative 
pathway i.e the α-secretase pathway.  
Promoting α-secretase cleavage is neuroprotective since it has been shown that 
the soluble part of APP has protective effects in cell models. Therefore, in addition to 
maintaining original levels of APP by alternate cleavage, this will also improve the 
toxicity caused by the amyloidogenic cleavage of APP. Passive immunotherapy using 
monoclonal antibodies has led to several adverse immune reactions in patients. Patients 
64 
have developed Human Anti-mouse antibodies or HAMA in treatments involving murine 
monoclonal antibodies. Earlier clinical trials using immunotherapy for AD were aborted 
because of T-cell related inflammation in the brain. Single chain antibodies against 
several antigens are being evaluated in clinical trials. Single chain variable fragments 
have several advantages over traditional antibody formats. Single chain antibodies that 
specifically inhibit BACE-1 cleavage of APP would be of immense value as potential 
therapeutics for AD. 
 
We hypothesized that Novel Disease Modifying immunotherapy with Single Chain 
Variable Fragment Antibodies targeted towards the BACE-1 cleavage site  on APP 
will decrease generation and toxicity of Aβ in Alzheimer ’s Disease. 
 
3.1 SPECIFIC AIMS 
AIM 1: “Biopanning” and screening of scFvs specific to the BACE-1 cleavage site on 
wild type APP from a non-immune human yeast display library 
Yeast display technology will be used to select for scFv specific to the BACE-1 
cleavage site on APP. In order to select for scFvs specific to the BACE-1 cleavage site on 
APP, a 15 amino acid biotinylated peptide containing the cleavage site on APP will be 
synthesized and used as an antigen. Biopanning will be performed using magnetic bead 
capture (with streptavidin or neutravidin coated magnetic beads and biotinylated antigen) 
for competition based selection of APP substrate binders. This will be followed by 
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Fluorescence Activated Cell Sorting (FACS) which will be used to eliminate Aβ binders 
before selecting for binders specific to the APP peptide using yeast double labeled with 
antigen + Streptavidin-phycoerythrin and Anti-cmyc + Goat anti-mouse Fluoroscene 
Isothiocyanate. Flow cytometry with double labeled individual clones will be used to 
further screen clones for scFv expression and binding to the APP peptide. Clones will be 
labeled with both Aβ and the antigen in order to pick yeast expressing scFv that 
specifically recognize the APP antigen but not Aβ. 
 
AIM 2: Expression and Characterization of BACE-1 cleavage site specific scFv in-
vitro and in APP over expressing cell models of Alzheimer’s disease. 
ScFv will be secreted and purified and characterized in in-vitro cell models of 
Alzheimer‟s Disease.ScFv isolated from the yeast library will be cloned into a soluble 
yeast expression vector and purified using Ni-NTA based Immobilized Metal Affinity 
Chromatography. Purified scFv will be analysed using techniques like Gel 
Electrophoresis and Western blotting using an scFvtag specific antibody (anti-v5 mouse 
monoclonal antibody). In vitro characterization will be performed to analyse the ability of 
the protein to recognize full length APP in APP overexpressing Chinese Hamster Overy 
(CHO) cells using immunofluorescence staining.  
Further,a co-immunoprecipitation assay will be used to pull down the scFv-APP 
immnune-complex using an anti-APP antibody and staining the western blot with the 
anti-v5 antibody. In addition, the ability of the scFv to interfere with Aβ generation and 
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toxicity will evaluated in the APP overexpressing cell line using Lactate Dehydrogenase 
Release (LDH release) assay and sandwitch ELISAs to measure Aβ levels in cells. 
 
AIM 3: Construction and intracellular expression of a Bispecific antibody fragment 
(tandem scFv) for simultaneously inhibiting BACE-1 cleavage and enhancing alpha-
secretase cleavage  
In order to combine BACE-1 inhibition with simultaneous activation of α-
secretase activity, a bispecific antibody will be constructed by linking the BACE-1 site 
specific scFv with a proteolytic scFv enhancing alpha-secretase cleavage previously 
isolated in our lab. Using standard molecular biology techniques like Overlap extension 
PCR and restriction enzyme double digestion, the DNA for both scFv will be combined 
and the fragment will then be cloned into a mammalian cell expression vector pSectag. 
This vector has a secretion signal and a c-myc tag which will enable production and 
secretion of the bispecific antibody and characterization using an anti-cmyc antibody. 
The DNA will be purified to remove endotoxins and transfected in mammalian cells over 
expressing APP in order to study the effect of the antibody on the APP proteolysis 
pathway. Immunoblotting will be used to verify the expression of bispecific scFv in cells. 
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Figure 3.1  Schematic of Diabody construction showing steps involving 
introduction of restriction enzyme sites and overlap extension PCR followed by cloning 
into a mammalian expression vector 
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AIM 4: Evaluation of the effect bispecific tandem scFv in APP overexpressing cell 
models  
The Bispecific scFv will be evaluated for its effect on APP proteolysis in APP 
over expressing cells. Two cell lines will be used to study the bispecific scFv -  Chinese 
Hamster Ovary (CHO) cells and H4 (human neuroglioma) cells over expressing APP. 
The Swedish mutation which occurs at the BACE-1 cleavage site makes APP at least a 
50 times better substrate for BACE-1 cleavage. However 85% of the Alzheimer cases are 
sporadic and do not contain the Swedish mutation. Both these cell models do not carry 
the Swedish mutation. Using immunoblotting techniques, APP levels and sAPPα levels 
will be quantified for cells expressing both APP and bispecific scFv versus cells 
overexpressing APP. In addition, a sandwich ELISA with an N-terminal and a C-terminal 
specific antibody will be used to measure Aβ levels in cells. An anti-β-actin antibody will 
be used to quantify levels of the protein β-actin and used as an internal control for all the 
lysates.  
 
AIM 5: Characterization of cell mechanisms involved in bispecific scFv treatment 
The effect of the bispecific antibody will be further characterized in order to study 
some of the mechanisms involved in rescuing the cells over expressing APP. 
Mitochondrial damage in Alzheimer‟s Disease is one of the most important signs of cell 
damage and cytotoxicity in Alzheimer‟s Disease. Using a dye that is sensitive to the 
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damage of mitochondria and the corresponding release of cytochrome C, cells will be 
stained to study the effect of bispecific scFv on mitochondrial damage. The effect of 
stress like exposure to hydrogen peroxide is known to increase susceptibility to 
mitochondrial damage in cells over expressing APP. This will be studied using nuclear 
staining and measuring Reactive Oxygen Species produced in cells. Further, Caspase-3 
assays will be used to study the activation of apoptotic pathways in cells. 
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CHAPTER 4 
Inhibiting β-Secretase Activity in AD Cell Models with Single Chain Antibodies 
Specifically Targeting APP 
4.1 Abstract  
The Amyloid-β (Aβ) peptide is produced from a larger precursor protein, 
Amyloid Precursor Protein (APP) by sequential proteolytic cleavage of APP first by β-
secretase then by γ-secretase. Most of the β-secretase processing of APP observed is by 
the Beta site APP Cleaving Enzyme-1 (BACE-1) enzyme and this makes it the principal 
therapeutic target for treatment of AD. BACE-1 also cleaves numerous other substrates 
with important physiological activity. So inhibition of BACE-1 function universally by 
targeting its catalytic site may have adverse side effects. We isolated a single chain 
variable domain antibody (scFv) from a human based scFv yeast display library that 
selectively inhibits BACE-1 activity toward APP. This scFv binds APP at the proteolytic 
site. In order to target APP but not soluble Aβ,  the iBSEC-1 scFv was selected such that 
it recognizes the BACE-1 cleavage site on APP but does not bind the adjacent highly 
antigenic N-terminal of Aβ. When added to CHO cells that overexpresses APP, the 
iBSEC1 scFv binds APP on the cell surface, reduces toxicity induced by APP 
overexpression, and reduces both intracellular and extracellular Aβ levels by around 
50%. This scFv does not contain the antibody Fc region and hence this construct does not 
pose the same risk of exacerbating inflammation in the brain like  full length monoclonal 
antibodies for development of potential therapeutics for Alzheimer‟s Disease. 
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4.2 Introduction 
Alzheimer‟s disease (AD) is one of the most prominent and devastating 
neurodegenerative diseases associated with aging. The disease causes progressive 
neuronal loss that destroys several functions of the brain resulting in dementia ultimately 
leading to death. The presence of neuritic plaques containing aggregates of 40 or 42 
amino acid long amyloid-β (Aβ) proteins and neurofibrillary tangles containing 
aggregates of the hyperphosphorylated protein tau
1; 2
 in the brain are the two primary 
neuropathological features of this disease. Aβ  normally exists in its monomeric form in 
the brain but can aggregate to form oligomers and ultimately fibrils which are found in 
the plaques of AD brains. Oligomeric forms of abeta both synthetic and dervided from 
cells/brain have been shown to be neurotoxic and disrupt learning and memory functions 
in animal models. According to the amyloid cascade hypothesis, the accumulation of Aβ, 
particularly the longer 42 amino acid form, leads to formation of toxic aggregates 
resulting in neurodegeneration, inflammation
3
, and subsequent formation of amyloid 
plaques
4. This is one of the leading theories that explains the pathogenesis of Alzheimer‟s 
Disease.  
Aβ is generated by proteolytic processing of the transmembrane amyloid 
precursor protein (APP). APP is approximately 700 amino acids long and is universally 
expressed in the brain. The three main enzymes that affect processing of APP into Aβ are 
the α-, β- and γ-secretases. In the amyloidogenic processing pathway, APP is first cleaved 
by the enzyme β-secretase, releasing a large soluble fragment called sAPPβ. The 
remaining membrane bound C terminal fragment (C-99) is subsequently imprecisely 
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cleaved by γ-secretase to release either Aβ40 or Aβ42
5
. APP can also be processed through 
an alternative non-amyloidogenic pathway where the enzyme α-secretase first cleaves 
APP releasing the soluble sAPPα fragment, and the shorter membrane bound fragment C-
83 is then further cleaved by γ-secretase to form the p3 peptide instead of Aβ (Figure 
4.1). While both β-secretase and α-secretase cleavages are lumenal, γ-secretase cleavage 
occurs within the membrane
6. Aβ is a natively unfolded protein found in healthy human 
brains but it can misfold and assemble into a variety of aggregate forms including several 
oligomeric species, some of which are very toxic to cells
7; 8; 9
 and a fibrillar form found in 
neuritic plaques characteristic of AD
1
.  Since accumulation and subsequent aggregation 
of Aβ leads to neurodegeneration, promoting non-amyloidogenic processing by 
increasing the activity of α-secretase enzyme or limiting amyloidogenic processing of 
APP by inhibiting β-secretase activity are promising disease modifying strategies for 
treating AD. 
The primary enzyme responsible for β-secretase cleavage of APP is the Beta site 
APP Cleaving Enzyme-1 (BACE-1), a 501 amino acid protein which belongs to the 
aspartyl protease family
10; 11; 12
. The enzyme cleaves APP substrates containing the 
Swedish mutation more efficiently than wild type APP, potentially accounting for the 
increased incidence of AD in people carrying these gene mutations
13
 . It is commonly 
found in the lumen of acidic vesicles of cells or the secretory pathway like the TGN and 
is most active at acidic where most of the APP cleavage happens. APP may be recycled 
into these compartments in order to facilitate cleavage by BACE-1.  
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In addition to APP, BACE-1 cleaves other substrates that might be of 
physiological importance. These include the β subunit of Voltage gated Sodium 
Channels
14
 , NRG-1 (involved in myelination)
15
 and the Low density Lipoprotein related 
Receptor Protein (LRP)
16
 . Numerous small molecule inhibitors such as OM99-2 have 
been developed as inhibitors of BACE-1 activity
17
 based on structure based design of 
inhibitors. BACE-1 knockout mice show signs of hypomyelination
15
 and impaired 
synaptic function
18
 and therefore, inhibiting BACE-1 enzyme activity towards all of its 
substrates might have detrimental effects. Since BACE-1 has physiologically important 
activity beyond APP cleavage, a more effective therapeutic strategy for AD would be to 
specifically block BACE-1 activity toward the APP cleavage site without interfering with 
BACE-1 activity toward other substrates. Binding the cleavage site of BACE-1 on APP, 
may be one way to achieve blocking of BACE-1 processing of APP. Binding to APP 
should ideally occur just upstream of the Aβ sequence to avoid also binding soluble Aβ. 
This is because, the BACE-1 cleavage site includes the N-terminal of Aβ, which is an 
immunodominant epitope 
19
,. 
       Immunotherapy involves the use of anitibodies as therapeutic agents. Antibodies are 
proteins that are highly specific in their recognition of antigens and play a pivotal role in 
the functioning of the immune system. While immunotherapies have been effectively 
used to treat several diseases
20
 , initial clinical trials to treat AD by immunizing patients 
with aggregates of Aβ were cancelled due to the occurrence of meningoencephalitis21 . In 
order to avoid potentially damaging inflammatory responses in the brain, single chain 
variable domain antibody fragments (scFv) which contain only the variable heavy and  
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light chain regions represent a promising alternative to antibodies since they do not 
contain the Fc region
22
, and  are significantly smaller potentially facilitating transport into 
the brain.  
ScFv are one of the most important class of recombinant antibody based 
therapeutics that are currently being developed for therapeutic and diagnostic purposes. 
Here we describe the isolation and characterization of an scFv fragment, iBSEC1, from a 
human yeast display library that binds the BACE-1 cleavage site of APP. The scFv 
inhibits BACE-1 catalytic activity toward APP, but does not bind soluble Aβ. The 
iBSEC1 scFv inhibits BACE-1 activity both in-vitro and in cell based assays decreasing 
both extracellular and intracellular Aβ levels by around 50%, and reducing toxicity 
induced by overexpression of APP in CHO cells. These results suggest that the iBSEC1 
scFv may have potential value as a therapeutic for AD by very selectively inhibiting 
amyloidogenic processing of APP.    
 
4.3 Materials and Methods  
4.3.1 Synthesis of APP Substrate  
The peptide consisting of amino acids APP 665-680 (wild type sequence) 
biotinylated at the C terminus was synthesized at the Proteomics and Protein Chemistry 
Lab in The School of Life Sciences, Arizona State University. 
 
75 
4.3.2 Preparation of Yeast Display antibody library   
A yeast library with a diversity of 10
9
 was obtained from the Pacific Northwest 
National Laboratory (Richland, WA) and used for bio-panning experiments essentially as 
described previously 
23
. Yeast were grown in selective SD-CAA media (Synthetic 
Dextrose – Casamino acids) at 30°C overnight until the OD600 was 2-3. Cells were 
centrifuged and resuspended in SG/R+CAA  expression media ( 20g/L Galactose, 20g/L 
Raffinose and 1g/L dextrose substituting for Dextrose in the growth media) and grown 
for 12 hours at 25°C. A total of 10
10 
yeast were used for magnetic bead enrichment 
studies. 
4.3.3 Magnetic Bead enrichment for APP peptide specific binders   
Since the N-terminal of Aβ overlaps with the antigen used, we developed a 
modified protocol to remove binders to Aβ. Magnetic bead enrichment (MACS) and 
FACS sorting were performed essentially as described previously with the following 
modifications 
24
. Induced culture was washed and incubated with 1 µM biotinylated APP 
peptide. The first round of selection utilized a competition based protocol with 
enrichment performed in the presence of the antigen and 200 nM Aβ42 without biotin 
attached. Yeast were then incubated with Streptavidin or Anti-biotin magnetic beads 
(Miltenyi Biotech, CA). After washing with  PBS + 0.05% BSA + 1mM EDTA, the yeast 
pellet was dissolved in 30 ml of the same buffer and loaded onto a Miltenyi MACS LS 
column(Miltenyi Biotech,CA). The column was loaded with 5 ml of yeast at a time and  
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then washed before loading more yeast. After loading all the 30 ml of yeast, the column 
was washed and finally a plunger was used to recover yeast binding the biotinylated APP 
peptide.  
 
 
Figure 4.1 Schematic showing magnetic bead enrichment using the Miltenyi 
Biotech MACS column  to isolate binders to a specific antigen  
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4.3.4 FACS Sorting to eliminate Aβ binders   
After 3 rounds of enrichment, yeast were grown and induced as described earlier 
and 10
7
 cells were labeled for FACS sorting. Fluorescent probes were purchased from 
Molecular probes (Invitrogen, OR). Yeast were labeled with biotinylated antigen 
followed by Streptavidin-PE (SAPE), with anti-cmyc antibody (Roche Applied Sciences, 
IN) followed by Goat Anti Mouse-FITC (GAM-FITC) or double labeled with both tags. 
Double labeled yeast were sorted on a BD FACS Aria Cell Sorter. In order to prevent 
amplification of N-terminal Aβ specific binders, a single round of negative selection was 
performed using 200 nM biotinylated Aβ42 by double labeling yeast with biotin-Aβ+ 
SAPE and anti-cmyc +GAM-FITC and collecting yeast that were positive for the c-myc 
tag but not for Aβ. Negative panning was followed by 3 rounds of positive selection for 
double labeled yeast with the biotinylated APP substrate which enabled amplification and 
selection of clones which bound the antigen but not Aβ. 
4.3.5 FACS Screening  
  Three different populations of yeast positively labeled for c-myc but with 
different affinities for the APP peptide were collected. Thirty clones from each pool were 
individually analyzed for APP substrate binding and c-myc expression by flow 
cytometry. Clones were sequenced to verify intact scFv sequences. A KD value for each 
clone was calculated using the Mean fluorescence intensity (MFI) obtained from FACS 
using seven different concentrations between 100 nM to 20µM as described 
23
. 
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4.3.6 Expression and Purification of anti-BACE-1 site specific clones   
YVH10 strain of yeast and the ppNL9 soluble expression vector were obtained 
from Pacific Northwest National Laboratory (Richland, WA). Two high binding clones 
selected based on specificity to the APP peptide but not Aβ (iBSEC1 and iBSEC2) were 
subcloned into the ppNL9 vector using gap repair homologous recombination and co-
transformation into YVH10 competent cells
24
 . For protein purification
25
 overnight 
cultures of each clone were used to inoculate cultures in SDCAA+Tryptophan. ScFv 
expression was induced by exchanging the media with Yeast 
extract/peptone/galactose/raffinose. Supernatants were concentrated to 50ml final volume 
using a Pellicon tangential flow system with a 10kD cut-off filter and exchanged into 
PBS. 1 ml Ni-NTA Agarose beads (Invitrogen, CA) were added and incubated at 4°C for 
2 hrs with gentle agitation. An imidazole gradient was used to elute the protein and 
fractions were dialyzed into PBS and analyzed.  
4.3.7 BACE-1 In-Vitro Inhibition Assay  
Inhibition of BACE activity by each clone was evaluated in-vitro using the 
Sensolyte 520 β-secretase assay kit (Anaspec, CA). Purified iBSEC1 and iBSEC2 scFvs 
were analyzed for in-vitro BACE1 inhibition using a Swedish APP substrate that contains 
a donor and acceptor fluorophore enabling Fluorescence Resonance Energy Transfer 
(FRET) measurement according to the manufacturer‟s protocol. The fluorescence of the 
cleaved substrate was recorded at an excitation/emission of 490/520. End point readings 
for iBSEC1, iBSEC2, PBS (vehicle control) and no inhibitor/vehicle were measured after  
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30 min. The assay was repeated three times and statistical analysis performed using 
ANOVA. This assay also enabled us to compare the relative affinity of scFvs toward the 
BACE-1 cleavage site of the Swedish-APP substrate. The iBSEC1 scFv was selected for 
further studies since it inhibited BACE-1 activity better than iBSEC2.   
4.3.8 Immunocytochemistry with CHO-APP Overexpressing Cells  
 A Chinese hamster ovary (CHO) cell line stably transfected with cDNA encoding 
mutant human APP751 (7PA2), was a kind gift from Dr. Dennis Selkoe (Harvard 
Medical School, Boston). Cells were grown in Dulbecco Modified Eagle medium 
(DMEM) containing 10% fetal bovine serum (Sigma-Aldrich, MO), 100 U/ml Penicillin, 
100 µg/ml Streptomycin and 2mM L-Glutamine. All other products were procured from 
GIBCO, Invitrogen, CA. Selection pressure was maintained using 150 µg/ml G-418 
(Sigma-Aldrich, MO). A solution of 0.25% Trypsin-EDTA (GIBCO, Invitrogen, CA) 
was used to detach cells in order to passage them. Cells were plated at a concentration of 
2x10
4
 cells/well in 8-well chamber slides (NUNC, NY) and grown for a day. Cells were 
washed twice with PBS and fixed with 3% paraformaldehyde in PBS. Cells were 
permeabilized with 0.1% Triton-X 100, blocked for 30 min with 3% FBS and 1%BSA in 
PBS and incubated with 1.3µM of iBSEC1 scFv over night at 4 °C. Cells were washed 
and incubated with 1/200 anti-v5 antibody followed by 1/300 goat anti mouse – FITC 
each for 1 hour at room temperature.  
In order to determine if the iBSEC1 scFv co-localized with acidic vesicles in the 
cells, 7PA2 cells grown as described above were incubated with scFv overnight. ScFv 
was removed and cells were then fixed and permeabilized as described above. Cells were 
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also simultaneously labeled with anti-v5 antibody and Alexaflour-594 goat anti mouse 
antibody (red) and Lysotrack-green dye for an hour at room temperature. Both 
fluorescent antibodies/probes were purchased from Molecular Probes (Invitrogen, CA). 
Slides were mounted using the Vectashield Mounting Medium (Vector Labs, CA) and 
visualized under a Leica SP2 confocal microscope. 
4.3.9 Co-Immunoprecipitation of iBSEC1 site specific ScFv with APP   
7PA2 cells were cultured, plated at a concentration of 0.4 X 10
5
 cells/ml in T-25 
flasks and allowed to attach. Cells were incubated with either iBSEC1 scFv or PBS. 
Supernatants and cell lysates were collected after 24 hours. In order to investigate if the 
scFv co-immunoprecipitated with APP, APP was immunoprecipitated from cell lysates 
and supernatants from T-25 flasks. Samples from iBSEC1 treated and buffer control 
flasks were incubated overnight with Rabbit anti-C terminal APP antibody. A 50% slurry 
of Protein-A Sepharose beads was incubated with the samples for 1 hour at 4°C to bind 
the antibody and precipitate the immunocomplex. Samples were boiled in Laemli buffer, 
centrifuged, separated on a 15% SDS-PAGE gel and transferred onto Nitrocellulose 
membranes. Blots were developed as described above. 
4.3.10 LDH Release Cytotoxicity Assay  
7PA2 cells were incubated with serum free media containing the iBSEC1 scFv 
(1.3µM or 0.65 µM), a control scFv or PBS. Supernatant samples were taken at 24hour 
and 48hour time points. Cytotoxicity due to APP overexpression and processing to Aβ 
was measured using an LDH kit (Sigma-Aldrich, MO) as described
26
 . Absorbance was 
measured as a difference between 490 nm and 690 nm wavelengths. The data are 
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reported for samples taken after 24 hours after incubation with scFv as percentages of 
control values obtained from three independent experiments. Consistent with the scFv-
APP complex immunoprecipitating after 24 hours, maximum protective effects of 
iBSEC1 were observed at the 24 hour time point and hence, this was chosen for all cell 
based assays except intracellular Aβ measurement. Data was collected from three 
independent experiments and analyzed using ANOVA. 
4.3.11 ELISA to measure cellular Aβ levels in 7PA2 Cells  
 To determine whether the iBSEC1 scFv altered APP processing and decreased Aβ 
levels in 7PA2 cells, cells were grown in T-25 flasks as described above and supernatant 
samples were collected at different time points and a Sandwich ELISA was performed to 
determine Aβ40 and Aβ42 levels as described previously
27
 . C-terminal Aβ40 and Aβ42 
specific antibodies were used for the capture of the Aβ species and an amino terminal 
antibody was used as the detection antibody. The antibodies were generated and purified 
at Mayo Clinic Monoclonal Antibody Core Facilities as described previously
28
. 
Intracellular Aβ levels were also determined from all cell lysate samples 48 hours after 
scFv was added. After washing with PBS, cells were lysed with 1x TBS buffer containing 
1% Triton X-100 and 1x protease inhibitor complex (PIERCE, Thermo Fisher Scientific, 
IL). Cell pellets were discarded after microcentrifugation and a BCA protein assay 
(PIERCE, Thermo Fisher Scientific, IL) was used to quantify the concentration of total 
protein in each sample. All experiments were repeated in triplicate.Data was analysed 
using t-tests. 
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4.3.12 Western Blots To Measure sAPP Levels   
 Supernatant samples taken after 48 hours of incubation from T-25 assays as  
described above, were separated on 15% SDS-PAGE gels and transferred onto 
nitrocellulose membranes. Membranes were blocked with 5% milk-PBS for 1 hour at 
room temperature and then probed with monoclonal antibody of 6e10 (Sigma-Aldrich, 
MO) at 1/1000 dilution overnight at 4°C followed by incubation with 1/1000 dilution of 
Goat anti-mouse IgG-HRP for 2 hours at room temperature. The intensity of sAPP bands 
were quantified using Image J software (NIH). Densitometry values are reported as ratios 
of samples containing scFv iBSEC1 with buffer control samples.    
 
4.4 RESULTS     
4.4.1 Isolation of anti-BACE site specific scFvs     
Biopanning against APP 665-680 – To isolate scFvs that inhibit BACE activity by 
binding the BACE cleavage site of APP, we performed three rounds of panning using 
magnetic bead based enrichment to select for scFvs binding the APP peptide. We then 
performed a negative panning step using FACS to remove cells expressing scFvs that 
also bound Aβ, collecting a sub-library with most Aβ binding clones removed (Figure 4. 
2(A), Quadrant 4). The sub-library was used to select for cells binding the biotinylated 
APP665-680 peptide (containing the BACE-1 cleavage site of wild type APP) utilizing 
three rounds of FACS sorting and enrichment.  
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Positive binding cells collected from the final round of FACS sorting were 
segregated into 3 pools, P1, P2 and P3, based on relative affinity toward the APP peptide 
(Fig 4.2(B)). We tested 30 clones from each pool for binding towards both the APP 
peptide and Aβ using flow cytometry. Tested clones from the highest affinity pool, P1, all 
bound both the APP peptide and Aβ indicating that all Aβ binding clones were not 
removed in the single round of negative panning. Clones from the P2 and P3 pools did 
not recognize Aβ and had variable affinity towards the APP peptide. We selected the 
highest affinity clone from each of the P2 and P3 pools which bound the APP peptide but 
did not bind Aβ, clones iBSEC1 and iBSEC2 (Fig 2(C)). We verified that these clones 
did not bind biotinylated Aβ 1-10 (data not shown). The KD value calculated from FACS 
for iBSEC1 was 604 nM (data not shown).   
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          Figure 4.2 Selection of yeast positive for APP-substrate : FACS sorting was used to 
remove Aβ binders and “pan” for yeast expressing scFv that bind the APP substrate. (A) 
Yeast double labeled with Aβ-biotin+ Streptavidin-PE and anti-cmyc+goat-anti mouse-
FITC. Yeast in Q4 were collected for further sorts (B) Sub- library from negative 
selection double labeled with APP substrate+streptavidin-PE and anti-cmyc+goat-anti 
mouse-FITC. Three distinct pools of yeast were collected and individual clones tested. 
(C) Binding specificity of iBSEC1 and iBSEC2 towards the APP substrate versus Aβ-
biotin. Data shown was obtained from three independent experiments.  
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4.4.2 Expression and Purification  
To obtain soluble scFv protein for further characterization, the iBSEC1 and 
iBSEC2 genes were cloned into the soluble expression vector pPNL9 and purified using 
Immobilized Metal Affinity Chromatography. Purified protein was verified by SDS-
PAGE and western blot (Figure 4.3).    
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            Figure 4.3 Purification of APP 665-680 specific scFvs - ScFv iBSEC1 and 
iBSEC2 were purified using Ni-NTA beads. Purified scFv was analyzed using SDS-
PAGE and western blost probed with anti-v5 antibody and goat anti-mouse IgG-HRP. (a) 
iBSEC1 is seen as a 35kD band in the SDS-PAGE gel  (b) Western blot showing iBSEC1 
and iBSEC2.  
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4.4.3 In-vitro characterization of iBSEC1 scFv 
            The ability of iBSEC1 and iBSEC2 to inhibit BACE-1 activity was investigated 
using a commercial BACE inhibition kit (Anaspec, CA) which utilizes an APP based 
peptide that contains the Swedish mutation instead of wild type APP. The Swedish 
mutation occurs close to the BACE-1 cleavage site of APP and is a better substrate for 
BACE-1 than wild type APP
13
 . Both iBSEC1 and iBSEC2 efficiently inhibit BACE-1 
activity toward the Swedish APP substrate (Figure 4.4). Activity was assayed at pH 4.5, 
the predominant pH in the endosomes where BACE-1 activity can occur
29
 . Since 
iBSEC1 inhibited BACE-1 activity more strongly than iBSEC2, iBSEC1 was selected for 
all further studies. 
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           Figure 4.4 In-vitro BACE-1 inhibition assay – A FRET substrate containing the 
Swedish APP cleavage site of BACE-1 was used to measure inhibition by scFvs. The 
Anaspec Sensolyte BACE assay was used to measure end point readings after 30 
minutes. Data were collected for three independent experiments and analysed using 1-
way ANOVA tests. * represents p < 0.05  
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4.4.3 Characterization of iBSEC1 scFv in an overexpressing cell line 
iBSEC1 scFv binds and co-immunoprecipitates with APP in 7PA2 cells -After 
demonstrating that iBSEC1 could inhibit BACE-1 activity in-vitro, we studied whether it 
could also inhibit BACE-1 activity in cells utilizing the cell line 7PA2, a CHO cell model 
over expressing wild type APP. Immunofluoroscence staining with iBSEC1 verified that 
iBSEC1 binds APP on the surface of cells expressing full length wild type APP (Figure 4. 
5(A)). Binding of iBSEC1 to APP expressed by 7PA2 cells was also verified using a co-
immunoprecipitation assay where a C-terminal APP antibody was used to 
immunoprecipitate the iBSEC1-APP complex (Figure 4.5(C)). We also investigated if 
iBSEC1 scFv was able to access subcellular acidic vesicles such as endosomes. When 
incubated with 7PA2 cells, the iBSEC1 scFv was internalized and colocalized with acidic 
vesicles in 7PA2 cells, as shown by overlap of scFv labeling in red with the Lysotrack 
dye labeling in green ( Figure 4.5(B)). 
4.4.4 iBSEC1 reduces Aβ levels and decreases toxicity in 7PA2 cells  
 Since iBSEC1 bound APP produced by 7PA2 cells, we determined whether it 
could inhibit APP processing and reduce Aβ induced toxicity in 7PA2 cells when added 
extracellularly to 7PA2 cells.  The iBSEC1 scFv induced a concentration dependent 
decrease in toxicity, decreasing toxicity to 80% of control values at a concentration of 1.3 
µM (Figure 4.6(A)). 
When incubated with 7PA2 cells, iBSEC1 scFv also substantially reduced both 
extracellular and intracellular Aβ levels as measured by sandwich ELISA, decreasing  
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extracellular levels to less than 60% of control values (buffer control) and intracellular 
levels to less than 50% of control values (Figure 4.6(B) and Figure 4.6(C)). No 
significant changes in Aβ levels were observed with the control scFv.   
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              Figure 4.5.Recognition of APP in 7PA2 cells – (a) 7PA2 cells labeled with scFv 
iBSEC1 followed by anti-v5 antibody and Goat anti-mouse-FITC imaged under a Leica 
SP2 confocal microscope. (b)Co-immunoprecipitation with anti-C terminal APP 
antibody. Lane corresponding to lysate from 7PA2 cells after 24 hours treated with scFv 
shows the iBSEC1 scFv band when probed with anti-v5 antibody and Goat anti-mouse 
IgG-HRP 
4.4.5 Increase in sAPP alpha levels after treatment with iBSEC1  
              Since iBSEC1 bound APP in 7PA2 cells and effectively reduced Aβ generation 
and subsequent toxicity, we further verified that iBSEC1 inhibited APP processing by 
BACE-1 by monitoring the levels of the alternatively generated APP cleavage product, 
sAPPα. This soluble fragment of APP is generated by non-amyloidogenic α-secretase 
cleavage, instead of β-secretase cleavage of APP. A 10% increase in sAPPα levels in the 
supernatants was observed in iBSEC1 treated cells compared to control cells (Figure 
4.6(D)).   
 
4.5 DISCUSSION      
               Improper processing and misfolding of proteins is a principal driving force 
behind several neurodegenerative diseases including AD, Parkinson‟s, Huntington‟s and 
prion diseases
6; 30; 31; 32
 .  In AD, increased biochemical processing of APP via the 
amyloidogenic pathway (Figure 4.1) increases levels of the Aβ protein resulting in 
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formation of toxic aggregate species and formation of amyloid plaques. In the 
amyloidogenic pathway, APP is first cleaved by β-secretase producing a large soluble 
ectodomain fragment sAPPβ, and a membrane bound 99 amino acid fragment termed C-
99
33
 .  Gamma secretase complexes further cleave the C-99 peptide through an imprecise 
mechanism to form primarily Aβ40 and Aβ42. Cleavage by β-secretase is considered to be 
the rate limiting step in the generation of Aβ from APP 34 and therefore represents a 
promising point for therapeutic intervention. 
BACE-1 is predominantly responsible for the β-secretase site cleavage of APP 11; 12; 
13
. BACE-1 knockout mice initially showed normal development, behavior and 
physiology 
35
 and several small molecules such as OM99-2 were studied as inhibitors 
against BACE-1. Because of cell permeability and P-glycoprotein efflux losses, many of 
the inhibitors have been modified in order to improve in-vivo functionality 
17
. While 
these results show promise for the treatment of AD, APP is not considered the primary 
substrate for BACE-1. Other substrates include the NRG-1 protein involved in 
modulation of myelination 
15
, the Low Density Lipoprotein Receptor-related Protein or 
LRP 
16
, Beta-galactosidase alpha 2,6 sialyl transferase (ST6-Gal1) 
36
, P-Selectin 
glycoprotein ligand-1 
37
 and the β subunit of Voltage gated Sodium Channels 14. Since 
BACE-1 may play an important role in regulating the function of these important 
substrates, there may be damaging long term effects caused by non-selectively inhibiting 
BACE-1 activity to limit APP processing. An alternative approach to avoid these 
potential negative side effects is to specifically inhibit the BACE-1 proteolysis of APP by 
binding the BACE-1 cleavage site on APP instead of binding the catalytic site of the 
enzyme itself.  
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       Here we show that the scFv iBSEC1, isolated from a yeast surface display library, 
specifically recognizes the BACE-1 cleavage site on APP, inhibits BACE-1 cleavage of 
APP and reduces Aβ generation in a mammalian cell line overexpressing APP. We used 
an antigen containing the BACE-1 cleavage site of wild type APP to isolate scFvs that 
bind the BACE-1 cleavage site of APP. This region also includes the strongly 
immunogenic N-terminal sequence of soluble Aβ 38. Since we wanted an inhibitor that 
selectively binds APP but not Aβ, we first performed a negative selection using FACS to 
remove clones that bound Aβ. While some strong Aβ binders did remain, as evidenced by 
the recognition of Aβ by the strongest binders in the P1 pool (Figure 4.2(B)), this strategy 
was successful in amplifying several yeast clones specific for the APP substrate and not 
Aβ. We selected 60 clones from cells recovered in Pools 2 and 3 (Figure 4.2(B)) from the 
biopanning process and selected the clone from each pool that had the highest affinity for 
APP, but that did not bind Aβ – iBSEC1 and iBSEC2 (Figure 4.2(C)). Of these two 
clones, the iBSEC1 scFv was selected for further studies since it more potently inhibited 
BACE-1 activity at pH 4.5 based on an in-vitro FRET assay (Figure 4.4). 
    While iBSEC1 was isolated against the wild type APP BACE-1 cleavage site, it also 
recognizes the Swedish APP variant. The Swedish variant contains a 2 amino acid 
mutation immediately upstream of the BACE-1 cleavage site leading to increased BACE-
1 processing 
1
. The iBSEC1 scFv efficiently inhibits BACE-1 activity at acidic pH (Fig 
4) which is important since significant BACE-1 processing of APP occurs in the acidic 
environment of the endosomes and BACE-1 has optimal activity at pH 4.5
29
. We showed 
that iBSEC1 recognizes full length APP expressed by 7PA2 cells and co-
immunoprecipitates with APP (Figure 4.5).   
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        When incubated with 7PA2 cells, the iBSEC1 scFv also significantly reduces both 
intra- and extracellular Aβ levels by around 50% and reduces corresponding cytotoxicity 
(Figure 4.6(B,C)). The iBSEC1 scFv reduced supernatant levels of both Aβ40 and Aβ42 by 
essential identical amounts (Figure 4.6(B,C)) as expected since iBSEC1 inhibits BACE-1 
activity but should not influence γ-secretase activity toward APP. Incubation with 
iBSEC1 also increased the levels of the α-secretase cleaved product sAPPα, in the cell 
supernatants after 48 hours by about 10% (Figure 4.6(D)). 
           BACE-1 cleavage of APP occurs in several cellular locations including endosomal 
compartments, where the acidic environment is optimal for BACE1 activity, and 
secretory pathways like the ER and Golgi
23. Aβ can be produced intracellularly in the 
endosomes or other regions while Aβ produced at the plasma membrane and in the 
secretory pathways may constitute the extracellular fraction of Aβ. However reuptake of 
Aβ from extracellular pools may also form a part of the intracellular Aβ pools in neuronal 
cells
39
.  Intraneuronal Aβ42 has been implicated in the early pathogenesis of the disease40 
as intracellular Aβ has a dynamic relationship with extracellular Aβ, and intracellular Aβ 
accumulation can precede extracellular deposition of plaques
41; 42
.  
          Since iBSEC1 effectively binds its substrate both at neutral (Figure 4.5(A)) and 
acidic (Figure 4.4) pH, the scFv can potentially inhibit BACE-1 processing of APP at 
different locations both inside and outside the cells. The iBSEC1 scFv co-localized with 
acidic vesicles such as endosomes in the 7PA2 cells (Figure 4.5(B)) indicating that 
iBSEC1 may be effective in inhibiting intracellular APP cleavage as well, a conclusion 
further supported by the nearly 50% reduction in intracellular Aβ levels (Figure 4.6(C)). 
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Therefore, iBSEC1 may reduce both toxic intra- and extracellular accumulation and 
aggregation of Aβ. 
      Monoclonal antibodies against the BACE-1 site of APP were previously studied as 
therapeutics for AD 
43; 44
. Since monoclonal antibodies contain the Fc region, they can 
trigger host immune responses, a potential problem since APP is ubiquitous in the brain. 
An active immunization clinical trial using aggregated Aβ to treat AD was halted because 
6% of the patients developed inflammation
21
 .  Non-human based antibodies such as 
rodent monoclonal antibodies are known to cause a human-antimouse antibody (HAMA) 
response and can cause kidney damage, anaphylaxis and inflammation
45; 46
. Since the 
scFvs developed here have been obtained from antibody libraries with a repertoire 
synthesized from human genes
47
 and do not contain the antibody Fc region, they may not 
suffer from some of the same inherent drawbacks of monoclonal antibodies, particularly 
for neuronal applications. Recombinant antibodies like scFvs are an important class of 
antibodies being developed for several clinical applications, and since they are much 
smaller than monoclonal antibodies (30kD compared to 150 kD for a full length IgG), 
they may potentially facilitate transport to the brain more readily
48
.  
         An intracellularly expressed scFv derived from a monoclonal antibody raised 
against the N-terminal Aβ 2-6 tetrapeptide EFRH which also contained an added ER 
retention signal, lowered Aβ levels in cell models49. The iBSEC1 scFv also reduces 
intracellular Aβ levels even though it is added extracellularly. Since iBSEC1 substantially 
reduces extracellular Aβ levels as well, extracellular addition of the scFv can effectively 
lower Aβ levels both inside and outside cells. Since iBSEC1 was detected in acidic 
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vesicles inside cells, even when added extracellularly, and since iBSEC1 specifically 
binds APP and not soluble Aβ, the scFv may be reducing intracellular Aβ levels by 
inhibiting BACE-1 processing of APP when recycled through endocytic vesicles.   
       While iBSEC1 can effectively reduce amyloidogenic APP processing in a cell model 
of AD, it results in only a slight increase in non-amyloidogenic processing (Figure 
4.6(D)). One approach to simultaneously increase non-amyloidogenic APP processing 
while inhibiting amyloidogenic processing is to combine iBSEC1 with a second scFv that 
can promote α-secretase activity.  We have shown that a proteolytic scFv with α-
secretase-like activity can promote non–amyloidogenic processing of APP and reduce 
toxicity in 7PA2 cells
50
. A bispecific antibody construct combining iBSEC1 which 
inhibits BACE activity and amyloidogenic processing of APP with an α-secretase like 
catalytic scFv which promotes non-amyloidogenic processing of APP substrates would 
allow a single therapeutic molecule to process multiple APP substrates through the non-
amyloidogenic pathway (Figure 4.1). The moderate KD value of iBSEC1 (~ 600 nM) may 
further facilitate processing of multiple APP target molecules since it will not irreversibly 
bind a single target.      
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CHAPTER 5 
Bispecific Tandem Single Chain Antibody Designed to Simultaneously Inhibit -
Secretase and Promote α-Secretase Activity toward APP Reduces Toxicity in Cell 
Models of AD 
5.1 Abstract   
Misfolding and aggregation of Aβ is thought to be an important early event in the 
pathogenesis of Alzheimer‟s Disease. Aβ is produced from the amyloid precursor protein 
(APP) by sequential proteolysis of APP by two enzymes, β and γ-secretases.  A third 
protease, α-secretase, cleaves APP in the middle of the Aβ sequence prohibiting 
formation of Aβ. Therefore generation of Aβ from APP can be controlled by tailoring the 
activity of these three proteases toward APP.  We previously showed that β-secretase 
activity toward APP could be selectively inhibited using a single chain antibody fragment 
(scFv) which binds the protease cleavage site on the APP substrate.  We also showed that 
α-secretase activity toward APP could be enhanced using a proteolytic scFv engineered 
to specifically cleave at the α-secretase site of APP.  Here we describe the construction 
and characterization of a novel tandem bispecific recombinant antibody DIA10D that 
combines the scFv which inhibits β-secretase activity (iBSEC1) with the proteolytic scFv 
containing a-secretase like activity (ASec1A).   
When expressed in H4 cells, a mammalian neuroglioma cell line over expressing 
APP, the DIA10D diabody dramatically reduces levels of extracellular Aβ by about 50% 
while simultaneously increasing the levels of the neuroprotective APP product, sAPPα. 
By simultaneously inhibiting β-secretase processing and increasing α-secretase 
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processing of APP, we can direct processing of APP away from an amyloidogenic 
pathway and towards a non-amyloidogenic pathway.  Since DIA10D activity has been 
designed to selectively target APP, this novel approach to modulate APP processing 
should not affect other endogenous activity of the proteolytic enzymes involved in 
processing of APP.  
5.2 Introduction    
Alzheimer‟s Disease (AD) is the most common neurodegenerative disease, 
affecting around 5 million people in the United States alone. AD is characterized by loss 
of memory and cognition ultimately leading to death 
1
. The two major pathological 
hallmarks of AD are the presence of extracellular Amyloid plaques and intraneuronal 
neurofibrillary tangles 
2
. According to the prevailing amyloid cascade hypothesis, an 
important early step in the progression of AD is the accumulation, aggregation and 
deposition of the beta-amyloid (Aβ) protein 3. Aβ, a natively unfolded protein, can self-
assemble into a diverse array of aggregate species including numerous different soluble 
oligomeric structures along with the distinctive insoluble amyloid fibrils found in AD 
brain tissue 
4
, 
5
.   
Imprecise proteolytic cleavage of the Amyloid precursor protein (APP) results in 
the generation of different length Aβ species, the most predominant forms having 40 or 
42 amino acids, where the longer form is more prone to aggregate.  Three different 
enzymes, α, β, and γ-secretases, determine whether APP is processed via the 
amyloidogenic pathway which generates Aβ, or a non-amyloidogenic pathway which 
generates a smaller fragment of Aβ.  In the amyloidogenic processing pathway, APP is 
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first cleaved by β-secretase and then by γ-secretase to generate Aβ.  In the non-
amyloidogenic pathway, APP is first cleaved first cleaved by α-secretase which cleaves 
in the middle of the Aβ sequence, and then by γ-secretase.4. Because of the critical role 
played by the various secretases in generation of Aβ, a variety of different approaches 
have been attempted to modulate the different secretase activities toward APP as 
potential therapeutics for AD 
6
.   
Amyloidogenic processing of APP can be blocked by inhibiting either β-, or γ-
secretase activity. Numerous studies have targeted BACE-1 activity toward APP.  A lot 
of them focused on inhibition of enzyme activity while a few targeted inhibition of APP 
cleavage 
7
,
8
,
9
. We previously reported that a single chain antibody variable domain 
fragment (scFv) which binds the BACE-1 site on APP but does not bind soluble Aβ, 
could reduce both extracellular and intracellular Aβ levels by about 50% in a cell model 
of AD 
10
.  Several studies have also targeted γ-secretase activity as a potential therapeutic 
for AD 
11
. However, recently a clinical trial of a  γ-secretase inhibitor failed as the drug 
was observed to worsen ability to perform daily functions, underscoring potential 
difficulties with this approach 
12
.  
Increasing non-amyloidogenic processing of APP by promoting α-secretase 
cleavage of APP or promoting proteolytic degradation of Aβ has also been studied.  
Several enzymes including Neprilysin (NEP) and Insulin Degrading Enzyme (IDE) 
cleave Aβ aiding in clearance of Aβ 13. However since these enzymes cleave other 
substrates preferentially compared to Aβ, 14; 15, non-target protease activity can limit the 
value of this approach for AD.   An alternative approach is to supplement a-secreatse 
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activity using proteolytic antibodies. We identified a proteolytic antibody fragments that 
cleaved Aβ and tailored activity of a proteolytic scFv towards the α-secretase cleavage 
site of Aβ 16.  The ASec1A proteolytic scFv inhibited aggregation and toxicity of Aβ in-
vitro and promoted non-amyloidogenic processing of APP in cell models of AD 
5
.  Since 
the iBSEC1 scFv inhibits amyloidogenic processing, and the ASec1a scFv promotes non-
amyloidogenic processing of APP, combining these two scFvs together has potential 
value to tailor beneficial APP processing in AD.    
There are different ways to generate recombinant bispecific scFvs, the two most 
common methods being to combine the two scFvs in tandem or as diabodies 
17
. Here we 
describe a novel and highly specific approach to simultaneously increase α-secretase 
cleavage and block BACE-1 cleavage of APP using an engineered tandem bispecific 
single chain variable fragment antibody (scFv) which combines an scFv inhibiting 
BACE1 processing of APP with a proteolytic scFv which promotes a-secretase 
processing of APP.  We show that combining both of these activities into a single 
bispecific construct provides synergistic effects that simultaneously inhibit 
amyloidogenic processing and promote non-amyloidogenic processing of APP.  The 
tandem scFv, DIA10D, when expressed in a human neuroglioma cells overexpressing 
APP (H4) decreases APP levels by 20%, reduces extracellular Aβ levels by 50%, and 
increases the neuroprotective sAPPα protein levels by 30% .   
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Figure 5.1 Schematic showing APP processing by the different secretases. 
Cleavage by β and γ secretases results in the synthesis of Aβ. APP can also be cleaved by 
α-secretase within the Aβ sequence which does not form Aβ. Bispecific scFv DIA10D 
was constructed to simultaneously inhibit β-secretase cleavage and increase α-secretase 
cleavage of APP. 
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5.3 MATERIALS AND METHODS    
5.3.1 Materials 
The pSectag expression vector used for cloning the DIA10D tandem scFv was 
provided by Dr. Levites. PCR amplification primers used to synthesize and subclone the 
bispecific antibody were purchased from Integrated DNA Technologies, and are listed in 
Table1. Platinum® Pfx DNA Polymerase was purchased from Invitrogen, CA. Mouse 
anti-cmyc 9e10 antibody, anti-beta actin antibody, Goat anti-mouse IgG-HRP and 3,3′-
Diaminobenzidine (DAB) substrate system were purchased from Sigma-Aldrich,MO. 
Mouse anti-Aβ 1-16 antibody 6e10 was purchased from Covance. Restriction enzymes 
and buffers were purchased from New England Biolabs,MA. All cell media components 
were purchased from GIBCO, Invitrogen except where noted otherwise. 
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Table 5.1 
Primers used for synthesis of DIA10D in pSecTag plasmid 
Primer Name Primer Sequence Purpose 
ASECDIAF 5‟ CCC AAG CTT GAT 
GTT TTG ATG ACC 3‟ 
Used to introduce HindIII 
restriction site for subcloning 
DIA10D  into the pSectag 
vector 
ASECDIAR 5‟ TGG CGC GCC AGT 
ATT ACC ATC AGT ACT 
CCG TTT CAG TGC AGA 
GAC AGT GAC CAG 
AGT CCC 3‟ 
Used to add a linker sequence 
at the C-terminus of the 
Asec1A scFv and a and 
restriction site at the N-
terminus of iBSEC1 scFv 
BSECDIAF 5‟GAT  GGT AAT ACT 
GGC GCG CCA CAG 
GTA CAG CTG CAG 
CAG 3‟ 
Used to introduce a common 
region before the N-terminus 
of iBSEC1 with the Asec1A 
scFv and the linker in order to 
enable overlap of both 
fragments 
BSECDIAR 5‟ GGG CCC TCC TCG 
AGC GGA TTT GAT ATC 
CAC TTT GGT CCC 3‟ 
Introduce Xho1 restriction 
site  at the C-terminus of 
iBSEC1(DIA10D)Where? in 
order to clone the bispecific 
antibody into pSectag 
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Figure 5.2 Schematic for the construction of bispecific antibody fragment, 
DIA10D. Asec-1A proteolytic scFv was combined with iBSEC1 scFv in tandem using 
overlap extension PCR to generate a 1500 kbp bispecific construct. This fragment was 
inserted into the pSectag mammalian expression vector. 
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5.3.2 Cell lines and maintenance  
H4 cells stably expressing wild type APP were a kind gift from Dr.Rudi Tanzi ( 
Mass. General Hospital, MA). Cells were grown in Dulbecco Modified Eagle medium 
(DMEM) containing 10% fetal bovine serum (Sigma-Aldrich, MO), 100 U/ml Penicillin, 
100 µg/ml Streptomycin and 2mM L-Glutamine. Selection pressure was maintained 
using 200 µg/ml G-418 (Sigma-Aldrich, MO). 0.25% Trypsin-EDTA was used to detach 
cells in order to passage them.  
5.3.3 Transfection and generation of stable cell lines  
 DNA was purified using Endofree Maxi kits (Qiagen,CA). Cells were plated in 
6-well plates and transfected using the Fugene HD transfection reagent (Roche, CA) 
according to manufacturer‟s instructions. Stable cells were selected by replacing 
transfection medium with media containing zeocin at the appropriate concentrations. 
Cells were transferred to T25 flasks and thereafter maintained with selection pressure 
(bispecific antibody expressing cells) at 250 µg/ml for H4-APP cells.  
5.3.4 Dot blots using concentrated supernatants from bispecific antibody expressing cells          
          Supernatants from cells with or without bispecific antibody expression were 
collected at different time points and concentrated 5x using Nanosep 30 kD filters 
(Sigma-Aldrich, MO). A 2 μl aliquot of sample was dotted on nitrocellulose membranes 
and left to air-dry. Blots were incubated in 5% milk-PBS for 1 hour at RT. Blots were  
further probed with 1/1000 dilution of anti-cmyc 9e10 antibody in 2% milk-PBS  
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overnight at 4˚C and 1/1000 dilution of Goat anti-mouse IgG HRP for 2 hours at RT. The 
DAB chromogenic substrate was used to develop the blots as per manufacturer‟s 
protocols.  
5.3.5 Western blots to detect bispecific antibody expression in cell supernatants    
5 ml of supernatants from cells with or without bispecific antibody expression 
were incubated with Ni-NTA beads overnight at 4˚C. Beads were washed twice with PBS 
, incubated with 1 ml of  SDS-PAGE sample buffer and boiled for 5 min. Samples were 
separated on a 15% SDS-PAGE gel and transferred onto nitrocellulose membranes. Blots 
were probed with 1°  9e10 and 2° Goat anti-mouse IgG-HRP as mentioned earlier. 
5.3.6 Measurement of APP & sAPPα in cells with and without bispecific antibody 
expression 
H4-APP with and without bispecific antibody expression were plated at a 
concentration of 10
6
 cells per flask in T25 flasks. After 2 days, supernatants were 
collected and cells were lysed using 0.1 % Triton X-100 in 1x TBS buffer(100 mM Tris 
150 mM Nacl ) with 1x Halt Protease Inhibitor Cocktail (Thermo-Scientific, IL). Total 
protein was analyzed using a BCA assay (Thermo-Scientific,IL). Equal amounts of 
protein were resolved on a 10% SDS-PAGE gel and transferred onto nitrocellulose 
membranes. Blots were probed with 1/1000 dilution of Aβ 1-16 6e10 antibody overnight 
at 4˚C and 1/1000 Goat anti-mouse IgG-HRP for 2 hours at RT. Blots with identical 
samples were simultaneously probed with 1/2500 Mouse anti β-actin antibody and 
1/1000 Goat anti-mouse IgG-HRP. Using Image J, densitometry was used  to calculate 
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intensity of the bands. Ratios of intensity of APP band intensity and β-actin intensity 
were compared.  
Equal volumes of supernatants were loaded on a 10% SDS-PAGE gel and 
separated. Samples were transferred to nitrocellulose membranes and western blots were 
probed with 6e10 antibody as described earlier. Intensities of bands are reported as a 
percentage of total intensity. All experiments were repeated in triplicates and p-values 
were calculated using t-tests . 
5.3.7 Measurement of Aβ levels using sandwich ELISA  
 Total Aβ levels were measured in supernatants from cells with and without 
bispecific antibody expression  using a sandwich ELISAas described previously 
10
. N-
terminal and C-terminal antibodies were used to capture and detect the abeta protein thus 
enabling higher sensitivities. 
5.3.8 LDH release cell cytotoxicity assay   
Cells were plated in T25 flasks as described in previous sections. Supernatants 
were collected from cells expressing only APP or APP plus bispecific antibody at 48 h 
and used for cell cytotoxicity analysis. LDH activity was measured using an LDH 
Release assay kit (Sigma-Aldrich, MO) as described [30]. Data were collected in three 
independent experiments and statistical analysis performed using t-tests.  
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5.4 RESULTS 
5.4.1 Construction and Expression of Bispecific antibody DIA10D.   
We generated a bispecific tandem scFv construct by combining the Asec1A scFv, 
a proteolytic scFv which has α-secretase-like activity with the iBSEC1 scFv which 
inhibits β-secretase activity by blocking the cleavage site of the APP substrate.  The 
bispecific scFv should increase non-amyloidogenic processing of APP by increasing α-
secretase cleavage while simultaneously decreasing amyloidogenic processing of APP by 
selectively inhibiting β-secretase processing. The two scFvs were joined using overlap 
extension PCR. Expression of diabody from cells could be readily detected in supernatant 
samples from both H4-APP  mammalian cells and CHO-APP (7PA2) cells 48 hours after 
transfection, showing the expected size of 56kD for the diabody (Fig 3(A,B)).  Only 
minimal expression of bispecific scFv was observed 6 hours after transfection, even after 
5x concentration of supernatant (Fig3C). Since bispecific could not be detected 6-hours 
after transfection, we used this time point as a low expression control sample to compare 
with higher expression time points. 
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Figure 5.3 Expression of Bispecific antibody DIA10D in supernatant of 
transfected cells. (A) Dot blot of 5x concentrated supernatants collected after 2 days 
probed with identical 1° and 2° antibodies. Clockwise from left, anti-PLB positive 
control, H4-APP + DIA10D, H4-APP + DIA10D (2days after transfection) and H4-APP 
media. (B) Western blot of cell media probed with 1/1000 1° anti-cmyc 9e10 antibody in 
2 % milk-PBS and 1/1000 2° Goat-anti Mouse IgG-HRP. From L->R Marker, 7PA2 
media(control), 7PA2 + DIA10D, H4-APP media(control), H4-APP + DIA10D and anti-
PLB scFv (Positive control). (C) Supernatants from 6h time points. From left to right – 
anti-PLB positive control, H4-APP supernatants(concentrated) and H4-APP + DIA10D 
supernatants(concentrated) from 3 different experiments. 
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 5.4.2 DIA10D reduces APP levels in AD cell models.   
Promoting α-secretase activity toward APP should reduce endogenous APP 
levels.  We determined how expression of the bispecific scFv construct DIA10D altered 
APP levels in a human neuroglioma cell line H4 that over expresses wild type APP and 
CHO cells overexpressing APP (7PA2). The bispecific antibody DIA10D substantially 
decreased APP levels in cell lysate samples by around 10% in both cases (Fig 5.4(a),(c) 
and Fig 5.5(a)). To compare APP levels, we normalized β-actin levels between cells and 
adjusted the APP levels accordingly (Fig 5.4(b)).  No difference in APP ratios between 
transfected and untrasnfected H4 cells were detected in cell lysate samples 6 hours after 
transfectionverifying that the decrease in APP is due to bispecific scFv expression (Fig 
5.4(d)). 
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Figure 5.4 Decrease in APP levels due to DIA10D expression in H4-APP cells (a) 
APP levels from controls and DIA10D expressing cells (b) Beta-actin bands for both 
control and DIA10D expressing cells (c) APP levels quantified as a ratio of beta-actin 
band intensities for H4-APP cells expressing DIA10D (d) APP levels at 6hour time point 
showing no significant change when bispecific scFv expression is minimal. All 
experiments were repeated in triplicates. * implies p < 0.05.  
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Figure 5.5 Decrease in APP levels in DIA10D expressing 7PA2 cells. (a) APP 
levels in 7PA2 control and DIA10D expressing cells. (b) APP levels quantified as a ratio 
of beta-actin band intensities for H4 cells expressing DIA10D.     
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5.4.3 DIA10D increases sAPPα levels in H4-APP cells  
 Increasing α-secretase activity in cells should decrease APP levels and increase sAPPα 
levels.  To verify that the DIA10D bispecific scFv does increase sAPPα level in 
transfected AD cell models, we tested supernatant samples taken at 48 hours.  There was 
a sharp increase in sAPPα levels in the transfected H4 cells compared to the 
untransfected cells. This increase in sAPPα levels combined with the decrease in APP 
levels in cells expressing the DIA10D bispecific scFv  indicate a substantial effect on 
APP processing (Fig 5.6(a), 5.6(b)). However in 7PA2 cells, we did not see a significant 
change in sAPP levels (Fig 5.6(c)). 
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Figure 5.6 Increase in sAPPα levels in H4-APP + DIA10D cells (a)Western blot 
showing sAPPα levels with DIA10D expression in comparison with control cells. (b) 
Relative band intensity of sAPP bands in H4 cells as a ratio of total intensity values. (c) 
Relative band intensity in 7PA2 cells as a ratio of total intensity values. Band Intensity 
was quantified using Image J software. Statistical analysis was performed using t-tests for 
3 independent experiments and p < 0.05 
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5.4.4 DIA10D reduces Aβ levels in cell supernatants  
Inhibiting β-secretase activity toward APP should results in a decrease in Aβ  
levels.  To verify that the diabody inhibits β-secretase processing of APP, we measured 
total Aβ levels in supernatants and lysates from H4-APP and H4-APP + DIA10D cells 48 
hours after transfection. A 50% reduction in extracellular Aβ levels was observed in the 
supernatants from cells expressing DIA10D  compared to control cells (Fig 5.7 (a)). 
While a slight reduction in intracellular Aβ levels was also observed the difference was 
not statistically significant (Fig 5.7(b)). 
5.4.5 DIA10D expression reduces toxicity in H4-APP cells  
We measured changes in toxicity in transfected and control H4 cells 48 hours 
after transfection by measuring LDH release.  A 15% decrease in LDH activity was 
observed in H4 cells expression the DIA10D diabody compared to control cells. (Fig 
5.7(c)) 
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Figure 5.7 Effects of DIA10D expression in H4-APP cells (a) Extracellular Aβ 
levels decreased significantly after 48 hours when measured by sandwich ELISA. p < 
0.05 and n= 3. (b) Intracellular Aβ levels were also measured at 48 hours but the decrease 
was not significant (c) LDH release was used to measure cell cytotoxicity and a decrease 
was observed in comparison with control cells after 48 hours from supernatant samples 
from 3 independent experiments. 
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5.5 DISCUSSION    
Protein misfolding and aggregation is a common feature found in several 
neurodegenerative diseases including AD, Parkinson‟s Disease (PD) and Huntington‟s 
Disease (HD) 
18
. The prevailing Amyloid Cascade Hypothesis of AD posits that 
aggregation and deposition of Aβ leads to pathogenesis. Aβ, a natively unfolded protein 
can misfold and aggregate to form a variety of different species including various 
neurotoxic oligomers and insoluble fibrils, and each of these forms has been the  target of 
different therapeutic strategies.  Aβ is produced from the large transmembrane precursor 
protein APP by sequential proteolysis by two enzymes, β-secretase and γ-secretase. 
Cleavage by β-secretase releases a large soluble fragment sAPPβ and a smaller 
membrane bound fragment C-99. The C-99 fragment is then imprecisely cleaved by the 
enzyme γ-secretase to generate different length Aβ forms, predominantly Aβ-40 and -42. 
APP can also be cleaved by α-secretase through the non-amyloidogenic pathway 
generating the  sAPPα fragment and membrane bound C83 19. BACE-1 was identified as 
the primary enzyme involved in cleavage at the β-secretase site 20, the γ-secretase was 
found to be a complex of enzymes like the Presenilin and Nicastrin 
21, and TNFα 
Converting Enzyme (TACE) and ADAM-10  have been suggested as α-secretase 
candidates 
22
. A genetic mutation at the BACE-1 cleavage site on APP called the Swedish 
mutation makes APP a much better substrate for BACE-1 cleavage causing an increase in 
Aβ deposition and early onset of the disease 23. Since the different secretases regulate 
generation of Aβ from APP, they are attractive therapeutic targets.   
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 BACE-1 cleavage of APP can occur in the secretory pathway like the ER and 
Golgi or the endosomes. The enzyme activity is optimal at acidic pH such as that in 
endosomes 
24
.  Several structure based inhibitors were characterized to inhibit BACE-1 
enzyme activity and have been modified to improve cell permeability and in-vivo efflux 
issues 
7
. We previously isolated an scFv, iBSEC1, that binds APP at the β-secretase 
cleavage site and reduces BACE-1 cleavage of APP
10
. The iBSEC1 scFv does not bind 
soluble Aβ even though it binds APP adjacent to the N-terminal of Aβ 10, therefore it 
should specifically inhibit APP processing without affecting soluble Aβ. When added to 
an AD cell model,  iBSEC1 very dramatically lowered both extracellular and intracellular 
Aβ levels. Since iBSEC1 can dramatically lower Aβ levels, it represents a promising 
route to inhibit amyloidogenic processing of APP.  Since the scFv does not contain an 
antibody Fc region, the risk of increasing inflammation in the brain is reduced.  A clinical 
trial utilizing active immunization against aggregated Aβ was canceled because of 
increased risk of inflammation in the brain 
25; 26
.  Inflammation is already an important 
problem in AD, and immunization protocols can risk acerbating this problem. However 
antibody fragments which lack the Fc region can still selectively target specific antigens 
without initiating an inflammatory response.   
 While inhibiting BACE-1 processing of APP is a promising approach to lower Aβ 
levels, an alternative approach is to lower existing Aβ levels by increasing clearance 
through proteolytic degradation.  Since brain clearance of Aβ is impaired in AD patients 
27, facilitating clearance of Aβ from the brain is also a promising therapeutic approach. 
Neprilysin, a metalloprotease involved in signaling in the brain, Insulysin or Insulin 
Degrading Enzyme (IDE), endothelin converting enzymes and angiotensin converting 
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enzyme have all been shown to proteolytically degrade Aβ 27. A decrease in levels of 
NEP have been correlated with increased Aβ levels in AD and Cerebral Amyloid 
Angiopathy (CAA) 
28
. Supplementing these enzymes has been proposed as therapeutic 
strategies 
29
, however since these enzymes have other preferred substrates, [15-16] 
unwanted side reactions are an important concern for potential therapeutic applications. 
 Furthermore, IDE also binds Aβ, which may interfere with receptor mediated 
clearance of Aβ from the brain 30.  The Low density lipoprotein associated receptor 
(LRP) and  the Receptor for advanced glycation of end products (RAGE) are both 
involved in receptor mediated clearance of Aβ from the brain 31; 32. To overcome 
potential drawbacks associated with proteolytic clearance of Aβ, we developed a 
proteolytic scFv, Asec1A that was engineered to selectively cleave APP or Aβ at the α-
secretase cleavage site 
5
. Affinity matured from a naturally occuring catalytic antibody, 
Asec1A specifically cleaves Aβ and reduces Aβ aggregation and toxicity towards SHSY-
5Y neuroblastoma cells in-vitro.  
The two scFvs, Asec1A and iBSEC1 represent promising approaches to control 
Aβ levels by promoting α-secretase cleavage of Aβ and APP and inhibitng BACE-1 
cleavage of APP.  While these scFvs show promise individually, combining the two 
scFvs into the single bispecific construct, DIA10D, leads to synergistic effects.  While 
Asec1A was engineered to cleave either APP or Aβ at their α-secretase sites., when it is 
combined with the iBSEC1 scFv, the diabody will preferentially bind APP but not 
soluble Aβ due to the presence of iBSEC1, and therefore the bispecific antibody will 
cleave APP preferentially over Aβ.  The diabody will simultaneously inhibit 
amyloidogenic BACE-1 processing of APP while promoting non-amyloidogenic α-
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secretase processing of APP. The goal is to decrease generation of Aβ from APP while 
increasing production of sAPPα a neuroprotective protein 22 that plays an important role 
in adult neurogenesis 
33
.  We generated a bispecific scFv, DIA10D,  by combining the 
Asec-1A scFv with the iBSEC1 scFv in tandem. When expressed in mammalian cells, the 
full length DIA10D tandem scFv is produced.  
 The bispecific scFv substantially lowers APP levels while simultaneously 
increasing sAPPα levels due to targetd α-secretase activity toward APP. The increase in 
sAPPα levels is consistent with our previous results showing that sAPPα levels were 
increased with Asec1A proteolytic scFv  treatment. With DIA10D treatment, while we 
did see increase in sAPPα levels in H4-APP cells, we did not see increase in sAPPα in 
7PA2 cells. The bands corresponding to DIA10D secretion suggest similar levels of 
expression in both H4-APP and 7PA2 cells and hence, the differential effects might 
potentially be due to differences in DIA10D reuptake and/or processing of APP in these 
cells. However, Asec1A by itself is not specific to APP since it also cleaves Aβ. 
Overcoming this lack of specificity, the presence of the iBSEC1 scFv on DIA10D should 
localize the proteolytic Asec1A to the β-secretase site of APP even while blocking 
BACE-1 activity. This should position Asec1A in the proximity of the α-secretase site 
increasing the local concentration or  “effective concentration“ of APP sensed by the 
proteolytic scFv.  Such increases in effective concentration can increase the catalytic 
efficiency of an enzyme by several orders of magnitude.  The iBSEC1 scFv is probably 
able to greatly increase the effectiveness of Asec1A.   
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The moderate Kd of iBSEC1 promotes reversible binding of the scFv to APP.  
Therefore the DIA10D should also reversibly bind APP which should allow the diabody 
to bind and cleave multiple APP substrates.  The proteolytic capacity of DIA10D enables 
the iBSEC1 scFv to inhibit b-secretase processing of multiple APP substrates instead of 
just a single substrate.  So the Asec1A scFv can increase the effectiveness of the iBSEC1 
scFv.  In support of this, the DIA10D lowered extracellular Aβ levels by over 50%, 
indicating reduced BACE-1 cleavage of APP. Similar reduction in Aβ levels were 
observed previously when 1µM iBSEC1 was added to cell cultures. Here the bispecific 
scFv concentration was estimated using a serial dilution of control scFv and we estimated 
it to be less than 400 nM. However intracellular Aβ levels did not decrease significantly 
with the diabody, even though a significant decrease was obtained with iBSEC1 alone.  
This could be because DIA10D may not be endocytosed as effectively as iBSEC1 or may 
be less stable in the endosomal compartments where APP cleavage occurs. While the 
bispecific scFv did not decrease intracellular Aβ, it did reduce toxicity compared to 
control cells with no DIA10D.   
Recombinant bispecific antibodies have been widely used for cancer therapeutic 
applications 
17
. Using bispecific antibodies has enabled specific killing of cancer cells by 
antigens like the carcinoembryonic antigen or the Epidermal growth factor receptor while 
activating cytokines, lymphocytes or NK cells 
34; 35
. To our knowledge, this is the first 
report of recombinant bispecific antibodies as a therapeutic application for Alzheimer‟s 
Disease. We show that a novel therapeutic tandem bispecific scFv DIA10D can 
selectively modulate APP processing, enhancing non-amyloidogenic proteolysis to 
generate the neuroprotective protein sAPP, while simultaneously inhibiting generatation 
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of Aβ. DIA10D is designed to selectively modulate processing of APP without 
interfering with other endogenous activity of native BACE-1 or α-secretase.   
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Chapter 6 
Anti- β Site Scfv Reduces Oxidative Stress in a Cell Model of Alzheimer's Disease 
6.1 Introduction   
Alzheimer‟s Disease is a neurodegenerative disease characterized by progressive 
loss of neurons which causes dementia and loss of cognition ultimately leading to death. 
AD is the most common cause of dementia in the United States and affects about 5 
million people 
1. Deposition of aggregate forms of the protein Aβ(either 40 or 42 amino 
acids long) is considered to be an important early event involved in the pathogenesis of 
the disease 
2. Aβ 40 or 42 molecules can aggregate to form various oligomeric3 and 
fibrillar structures. AD brains contain deposits of fibrillar Aβ called amyloid plaques and 
deposits of aggregate forms of tau protein called Neurofibrillary tangles 
4. The protein Aβ 
is generated in the brain by proteolytic cleavage of the Amyloid Precursor Protein (APP) 
by β and γ-secretases 5 . Various oligomeric forms of Aβ 6; 7; 8  have been reported and 
recently, cell and brain derived oligomeric Aβ species have been shown to be neurotoxic 
as well 
9
.    
 While accumulation and aggregation of Aβ induces neurotoxicity, its mechanisms 
are not entirely clear. Oxidative stress is one factor that has been implicated in toxicity 
10
. 
Mitochondria are the energy producing centers of the cells and produce ATP which is 
used for several different neuronal functions. Oxidative stress can mediate itself through 
damage to the mitochondria. Several effects of oxidative stress have been investigated 
involving the Aβ protein 11; 12. Previous research has also shown that increase in Reactive 
oxygen species (ROS) as one of the oxidative damage effects of synthetic Aβ in-vitro 13; 
14
. ROS are synthesized from the superoxide precursor and it has been suggested that 
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direct interactions of Aβ with the mitochondria may result in ROS generation. Indeed, Aβ 
has been shown to interact with the mitochondrial membranes and also disrupt the normal 
fission-fusion balance that is important for healthy neurons 
15
.  
Aβ has been shown to inhibit Cytochrome-C oxidase function and similar 
reduction was also observed in the brains of AD patients 
16. Synthetic Aβ oligomers like 
ADDL have been shown to induce ROS generation and oxidative stress through a 
mechanism dependant on NMDA receptors 
17
 . Eckert et al showed that in PC12 cells 
overexpressing mutant forms of APP, mitochondrial membrane potentials were reduced 
and ATP generation was reduced 
18
 when exposed to stress (incubation with hydrogen 
peroxide) . They also reported decrease in cytochrome-C levels and an increase in 
Caspase-3 activity in both Swedish and wild type APP expressing PC12 cells 
12; 18
. These 
studies used levels of Aβ much closer to the physiological levels found in the brain rather 
than in-vitro experiments.. The results seemed to suggest that the elevated levels of Aβ 
may prime the cells towards damage through these pathways. 
We previously reported the identification of an scFv iBSEC1 specific to the 
BACE-1 cleavage site on APP 
19
. This might be a potentially safer approach since 
BACE-1 has several other important physiological substrates 
20; 21; 22
. Knockout of 
BACE-1 effects myelination and inhibition of BACE-1 activity may have other similar 
adverse effects 
23
. iBSEC1 scFv was previously shown to reduce both extracellular and 
intracellular Aβ levels in the 7PA2 cells 19. Here we show that treatment of 7PA2 cells 
(CHO cells over expressing APP) and H4-APP cells with iBSEC1 before treatment with 
hydrogen peroxide protects these cells from damage due to oxidative stress. iBSEC1 
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treatment reduces ROS generation and damage to the mitochondrial membrane in both 
cell lines. In addition, it also reduces Caspase-3 levels in 7PA2 and H4-APP cells when 
compared with a control scFv. ScFv iBSEC1 also reduced cell damage as indicated by 
Hoescht staining.  ScFv like iBSEC1 can potentially be useful for therapeutic purposes 
since they inhibit BACE processing of APP and generation of abeta thereby decreasing 
the oxidative stress caused by APP overexpression in cell models. 
 
Figure 6.1 Mitochondrial membrane potential and ATP levels are significantly 
decrease in H4 cells over expressing APP. Similarly, H4 cells treated externally with 
increasing concentrations of Aβ42 also show a dose dependent decrease in membrane 
potential and ATP levels 
18
. 
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6.2 Materials and Methods 
6.2.1 Purification of iBSEC1 scFv  
The scFv was purified using Ni-NTA beads as described previously. Briefly, 
overnight cultures of yeast were grown in SDCAA+Tryptophan. ScFv expression was 
induced by changing the media with Yeast extract/peptone/galactose/raffinose. Using a 
Pellicon tangential flow system, supernatants were concentrated with a 10kD cut-off filter 
and exchanged into PBS. 1 ml Ni-NTA Agarose beads (Invitrogen, CA) were added to 50 
ml of supernatant and incubated at 4°C for 2 hrs with gentle agitation. An imidazole 
gradient was used to elute the protein. Fractions were analyzed and pooled together after 
dialysis. 
6.2.2 SDS-PAGE and Western Blot for scFv  
Various elutions were analyzed on a 15% SDS-PAGE gels and stained with a 
Silver staining kit (Thermo-scientific, MA). Samples were also transferred onto 
nictrocellulose membranes and blocked with 5% Milk-PBS for 1 hour at RT. Blots were 
probed with 1/1000 anti-v5 antibody in 2% milk-PBS followed by 1/1000 Goat anti-
mouse IgG-HRP in 1%milk-PBS and developed with Diaminobenzidine (DAB) (Sigma-
Aldrich,MO). 
 
6.2.3 Maintenance of CHO-APP (7PA2) cells  
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 A Chinese hamster ovary (CHO) cell line stably transfected with cDNA encoding 
mutant human APP751 (7PA2), was a kind gift from Dr. Dennis Selkoe (Harvard 
Medical School, Boston). Cells were grown in Dulbecco Modified Eagle medium 
(DMEM) containing 10% fetal bovine serum (Sigma-Aldrich, MO) supplemented with  
1% L-Glutamine (200mM stock), 1% Pen-Strep ( 10000 U/ml Penicillin, 10000 µg/ml 
Streptomycin stock). All these products were procured from GIBCO, Invitrogen, CA. 
Selection pressure was maintained using 150 µg/ml G-418 (Sigma-Aldrich, MO). A 
solution of 0.25% Trypsin-EDTA (GIBCO, Invitrogen, CA) was used to detach cells in 
order to passage them. Cells were plated in 96-well flasks at a density of 10
4
 per well and 
allowed to attach overnight prior to scFv treatment. 
6.2.4 Reactive Oxygen Species (ROS) assay  
7PA2 cells were plated at a density of 10
4
 cells per well in 96-well plates and 
allowed to attach overnight. Cells were incubated with 1.3 µM of iBSEC1 scFv or control 
scFv for 48 hours based on our previous results on reduction in Aβ levels. ROS levels 
were measured using 2,7-dichlorofluoroscein diacetate (DCFH-DA) as the fluorescent 
probe. DCFH-DA is oxidized to a highly fluorescent form dichlorofluorescein (DCF) in 
the presence of ROS.  DCFH-DA was added at a final concentration of 10µM to the cell 
media and incubated for 1.5 hours. Media was aspirated and cells were washed with PBS. 
Cells were incubated with 1mM Hydrogen Peroxide for 4 hours and ROS generation was 
measured using a spectrophotometer with excitation-emission of 485-535 nm. 
6.2.5 JC1 assay for Mitochondrial Damage 
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JC1 is a dye that can be used to measure mitochondrial membrane potential. 
Depending on the membrane potential of the mitochondria, JC1 forms aggregates which 
are indicated by a shift in fluorescence. Cells were plated at a density of 10
4
 cells per well 
in 96-well plates and incubated with iBSEC1 scFv as described above.When JC-1 
aggregates in healthy mitochondria, the fluorescence is observed at 529 nm(red) while 
depolarization results in a shift of fluorescence to 590 nm (green). JC-1 was added to the 
cells at a final concentration of 100 µM and cells were incubated for 1.5 hours. After 
hydrogen peroxide treatment as described above, red/green fluorescence ratios were 
recorded in order to analyze mitochondrial health. 
6.2.6 Caspase-3 activity assay  
Activation of caspase-3 was analyzed using the SensoLyte Caspase-3/7 assay kit 
from Anaspec Inc. Cells were plated at a density of  10
4
 cells per well in 96-well plates. 
This assay was used to measure the cleavage of the substrate Ac-DEVD-AFC as 
described previously. Fluorescence was recorded at an Excitation-Emmission of 380-500 
nm.  
6.2.7 Nuclear staining  
 7PA2 cells were plated at a density of 10
4
 cells per well in 96 wells and allowed 
to attach overnight. Cells were treated with iBSEC1 or control scFv as mentioned 
previously. In order to assess cell damage, nuclei were stained with Hoescht 333452 dye 
(Thermo-scientific,MA). Cells were fixed with 4% paraformaldehyde and permeabilized. 
Hoescht dye was added to the cells at a final concentration of 1 µM. After 15 min 
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incubation, cells were washed with PBS and imaged using a Zeiss Fluorescence 
microscope. 
6.3 Results 
6.3.1 Purification of iBSEC1 scFv   
iBSEC1 scFv was purified using IMAC as described above. The SDS PAGE gel  
and western blot showed a single band approximately at 35 kD corresponding to the 
iBSEC1 scFv as reported previously
19
 . 
6.3.2 Reactive Oxygen Species Assay   
7PA2 cells were pre-treated with iBSEC1 scFv or a control scFv for 48 hours 
before exposure to hydrogen peroxide.  4 hours after addition of hydrogen peroxide, a 
decrease in ROS generation was observed with iBSEC1 treatment. This was observed for 
both 500µM and 1000 µM treatment with hydrogen peroxide. Data is represented as 
percentage of ROS levels measured for control scFv. 
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Figure 6.3 Ratio of ROS levels for iBSEC1 treated cells with control scFv treated 
cells (% of ROS levels for iBSEC1 treated/control scFv treated cells) after treatment with 
500 µM and 1000 µM scFv. (a) 7PA2 cells (b) H4-APP cells * p < 0.05. n = 3   
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6.3.3 JC1 Mitochondrial Membrane Potential assay   
Using the JC-1 dye we measured the ratio of red/green fluorescence after 
incubation with peroxide. A decrease in membrane depolarization was observed in 
iBSEC1 treated samples in comparison with control scFv treated samples as evidenced by 
an increase in the red/green fluorescence ratios.  
 
  
 
Figure 6.4 Red/Green (R/G) JC1 dye fluorescence ratios for both iBSEC1 and 
control scFv treated cells when exposed to 1000 µM scFv. An increase in red/green 
fluorescence was observed. * p < 0.05. n = 3. (a) 7Pa2 cells (b) H4-APP cells 
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6.3.4 Caspase-3 activation assay  
Hydrogen peroxide has been shown to cause elevated Caspase-3 cleavage in cells 
over expressing mutant forms of APP . Here, we found a decrease in Caspase-3 cleavage 
when 7PA2 cells were pre-treated with iBSEC1 in comparison with control scFv 
treatment.  
 
 
Figure 6.5 A decrease in Caspase-3 activity after pre-treatment with iBSEC1 scFv 
was observed when incubated with 1000 µM scFv. * p < 0.05. n = 3. (a) 7PA2 cells (b) 
H4-APP cells 
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6.3.5 Nuclear morphology staining 
Nuclear morphology of cells incubated with iBSEC1 or control scFv was assessed using 
Hoescht staining. A reduction in intensity of fluorescence suggested decrease in damage 
due to apoptosis after exposure of cells to hydrogen peroxide. 
(A)                                                                (B) 
             
Fig 6.5 Changes in nuclear morphology (A) 7PA2 cells incubated with control 
scFv stain brightly with Hoescht dye (B) 7PA2 cells incubated with iBSEC1 show 
reduced staining with Hoescht dye. Images were taken using a Zeiss Fluorescence 
microscope at 40x. 
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6.4 Discussion 
Several neurodegenerative diseases involve the deposition of misfolded proteins 
as the central cause of disease pathogenesis. These include Alzheimer‟s Disease (AD), 
Parkinson‟s Disease (PD), Huntington‟s Disease (HD) and Amyotrophic Lateral 
Schlerosis (ALS) 
4; 24; 25. Alzheimer‟s Disease is the most common neurodegenerative 
disease. Aβ40/42 are highly hydrophobic proteins that tend to aggregate and form smaller 
oligomers and eventually large insoluble fibrils that are found in plaques 
26.  Aβ is 
produced from a larger protein called the Amyloid Precursor Protein. Cleavage by the 
enzyme β-secretase followed by cleavage of the membrane bound fragment C-99 by the 
enzyme γ-secretase results in the formation of this amyloidogenic protein. APP can also 
be cleaved by the enzyme α-secretase 27 .  
 Mutations in the APP sequence can lead to Familial forms of AD. Several of these 
are centred around the β and γ secretase cleavage sites 4. The Swedish  mutation 
(K671M672L) at the β-secretase site on APP results in early onset of Alzheimer‟s 
Disease because it makes APP a 50-100 times better substrate for amyloidogenic 
cleavage 
28
. Other mutations which are centered around the γ-secretase like the Indiana 
mutation (V717F), also result in Familial forms of AD. In mouse models expressing APP 
carrying these mutations, deposition of Aβ aggregates and neurodegeneration has been 
reported similar to human AD brains 
29
.  Walsh et al constructed a cell model with CHO 
cells overexpressing APP with the V717F mutation (7PA2) cells. 7PA2 cells secreted Aβ 
and formed low n-oligomers that were characterized extensively 
30. These “cell-derived” 
oligomers were purified and shown to disrupt Long Term Potentiation when added to 
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hippocampal slices and in-vivo 
31
. Further, they also showed that these cell derived 
oligomers of Aβ reduce dendritic spine density in a pathway dependent on interaction 
with NMDA receptors and trigger the MAPK pathway 
31
. Similarly, Quiroz-Baez et al 
showed that neuronal cells overexpressing even normal levels of wild type APP show 
signs of oxidative stress and elevated levels of p-JNK. (Ricardo Quiroz-Baez
a
, Emilio 
Rojas
a
 andClorindaAriasNeurochemistryInternationalVolume 55, Issue 7, December 
2009, Pages 662-670) 
 In contrast with the in-vitro experiments involving Aβ, cell models of APP 
overexpression may produce Aβ at a concentration closer to that of physiological 
concentrations of Aβ in the brain 32. Here we show that in comparison with a control anti-
PLB scFv , iBSEC1, an scFv that specifically recognizes the BACE-1 cleavage site is 
able to reduce oxidative damage in CHO cells over expressing V717F APP when treated 
with hydrogen peroxide. It has been previously shown that treatment with hydrogen 
peroxide results in elevated levels of ROS suggesting some sort of increase in 
vulnerability towards oxidative damage but pre-treatment with iBSEC1 reduced these 
effects. Similarly, we observed that iBSEC1 also reduced mitochondrial membrane 
depolarization as evidenced by the increase in Red/Green ratio of JC-1 fluorescence. We 
also analyzed if there were changes in relative amount of Caspase-3 activation and 
observed a decrease in iBSEC1 treated cells. In addition, Hoescht staining showed a 
decrease in staining. Taken together, it suggests that iBSEC1 may be protective from cell 
damage due to oxidative stress. 
145 
 Oxidative stress and mitochondrial damage are broad effects that have also been 
implicated in other diseases of the brain like Parkinson‟s disease, ALS and Huntington‟s 
disease 
33
. Rather than using inhibitors of a particular pathway that is triggered due to 
oxidative stress and may have other consequences when inhibited, there is a need to 
develop disease modifying therapeutics in combination with effective diagnostics that are 
specific for Alzheimer‟s disease in order to help control progression of the disease. 
Keeping in mind this rationale for therapeutic development, we isolated iBSEC1 scFv 
from a human yeast antibody display library. iBSEC1 recognized full length APP but not 
Aβ and reduced levels of intracellular and extracellular Aβ 19. Here, treatment of iBSEC1 
reduced the priming towards oxidative stress reported by several previous studies 
characterizing exposure to hydrogen peroxide in APP over expressing cells. This may 
potentially be due to the reduction in Aβ levels after iBSEC1 treatment that we reported 
previously 
19. Production of Aβ oligomers and these neurotoxic effects like oxidative 
stress, may appear several years earlier than the deposits of plaques in Alzheimer‟s 
Disease 
34
. Hence, contingent on the successful development of a reliable diagnostic for 
early stage identification of the disease, therapeutics like iBSEC1 can interfere with 
disease progression and help control further neurodegeneration.  In combination with 
stimulation of α-secretase cleavage, iBSEC1 may potentially steer the cleavage of APP 
towards the non-amyloidogenic pathway.  
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Chapter 7 
Conclusions and Future Work 
Early diagnosis and treatment for Alzheimer‟s Disease is one of the important 
problems faced by the healthcare industry. Since it affects about 5 million people in the 
United States and is a huge burden on the healthcare industry, extensive research is being 
carried out for therapeutic and diagnostic development.  Deposition of the misfolded 
forms of the protein Aβ is considered crucial for progression of the disease.  Hence, 
several strategies have focused on trying to control Aβ levels or controlling aggregation 
of the protein. We have isolated a recombinant antibody fragments that recognize APP 
and inhibits BACE-1 cleavage and also combined this with a proteolytic scFv that 
stimulates non-amyloidogenic cleavage of APP through the α-secretase pathway. These 
antibody fragments are derived from human sequences and hence, they do not contain the 
Fc region that can potentially lead to inflammation like monoclonal antibodies. Using 
monoclonal antibodies that target APP might initiate an immune reaction since APP is 
widely expressed in the brain. Single chain antibodies retain the antigen specificity of the 
parent IgG but are less immunogenic and much smaller which may be beneficial for 
delivery to the brain.  
7.1 Isolation and characterization of scFv against the BACE-1 cleavage site on APP 
  We isolated a recombinant single chain antibody fragment iBSEC1 from a non-
immune human yeast display library. Using magnetic bead based and FACS based 
panning, we were able to successfully isolate iBSEC1 such that it was specific to APP but 
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did not recognize the adjacent highly immunogenic N-terminus of Aβ. After single clone 
analysis, the scFv iBSEC1 was sub cloned into a soluble expression vector and purified 
using Ni-NTA IMAC chromatography. After confirming the purification of the scFv, we 
characterized iBSEC1 in-vitro using FRET and in CHO cells overexpressing a mutant 
form of APP (7PA2 cells). iBSEC1 co-immunoprecipitated with APP and it also  labeled 
APP on the cell surface. Internalization of the scFv showed that it co-localized with 
acidic vesicles. BACE-1 cleavage is considered optimal at pH 4.5. In addition, we also 
showed a decrease in extracellular and intracellular Aβ. Since intracellular Aβ has been 
implicated in initial stages of neurotoxicity, this is quite a significant observation. Also, 
we performed the selection and binding assays at neutral pH suggesting that iBSEC1 may 
be  able to be functional at both acidic pH and neutral pH and may therefore be able to 
block BACE-1 cleavage in multiple locations as has been observed. The scFv iBSEC1 
recognized APP and prevented BACE-1 cleavage of APP in-vitro and in cell models.  
7.2 Synthesis and Characterization of bispecific scFv iBSEC1 
APP can either be cleaved by BACE-1 or the enzyme α-secretase. This pathway 
results in non-amyloidogenic cleavage of APP and release of the soluble form of APP 
called sAPPα has been shown to have neuroprotective effects. We successfully generated 
a bispecific antibody that combined the iBSEC1 scFv with a proteolytic antibody Asec1A 
previously shown to increase α-secretase activity. Asec1A reduced APP levels and 
increased sAPP levels. The bispecific scFv DIA10D increased sAPP release and 
decreased external Aβ levels suggesting that we successfully modulated APP cleavage 
towards the non-amyloidogenic pathway in H4 cells over expressing APP.  DIA10D 
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combines both strategies of therapeutic development based on the APP pathway. While 
the moderate Kd of iBSEC1 may limit the ability of the scFv to block APP cleavage by 
itself, combining with Asec1A will ensure that after binding, the APP is cleaved and the 
moderate Kd may enable dissociation and binding of another APP molecule. Asec1A was 
shown to cleave both APP and Aβ and DIA10D bispecific scFv makes the cleavage at the 
α-secretase specific towards APP. Bispecific antibodies have never before been applied 
to neurodegenerative diseases and this is the first application of the same.  
7.3 Characterization of iBSEC1 in 7PA2 cells 
Aβ mediated neurotoxicity has been extensively characterized. Oxidative stress is 
one of the important effects of increased Aβ exposure as observed in cell models as well 
as mouse and human brains. Mitochondrial damage is one of the consequences of 
elevated levels of oxidative stress. In APP over expressing cells, exposure to hydrogen 
peroxide results in an increase in ROS levels, Caspase activation and mitochondrial. We 
showed that iBSEC1 scFv reduces this type of damage when 7PA2 cells are pre-treated 
with the scFv before exposure to hydrogen peroxide. The iBSEC1 scFv successfully 
reduced ROS levels and mitochondrial membrane depolarization and also reduced 
Caspase-3 activation, which is one of the enzymes involved in the apoptotic pathway in 
the cells.  
Recombinant antibody display combined with in-vitro selection of recombinant 
antibodies and antibody engineering are powerful tools that can be used for therapeutic 
development. Phage display has been used successfully by our lab to isolate various 
conformation specific antibody fragments with potential therapeutic and diagnostic 
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applications in combination with Atomic Force Microscopy (AFM). Here, we 
successfully isolated scFv from a non-immune human yeast display library against APP 
but not a closely related antigen showing that competition based magnetic selection and 
FACS based negative panning can be used to eliminate binders to other undesirable 
antigens. Several recombinant and engineered antibodies are being tested in clinical 
trials. Bispecific antibodies are part of these candidate recombinant antibodies being 
developed for therapeutic and diagnostic applications and one of the most common 
formats used for Cancer immunotherapy.  
To our knowledge, we have successfully engineered the first bispecific antibody 
for application in neurodegenerative diseases and successfully used it to modulate APP 
processing.   scFv iBSEC1 and DIA10D are excellent candidates for further investigation 
in cell models and in mouse models. The strength of these techniques is that they are 
economical and can be entirely performed in-vitro without needing immunization of mice 
with the relevant antigen. These techniques and concepts are also powerful because they 
can be applied towards a wide range of antigens for diagnostic and therapeutic 
applications involving other neurodegenerative diseases or even other diseases like 
various types of cancers. 
7.4 Delivery across the Blood Brain Barrier 
Delivery into the brain is one of the major issues with treatment of 
neurodegenerative diseases. The human brain has evolved to isolate itself from 
pathogens, toxins and other harmful biological substances by developing a barrier of 
endothelial cells that prevents free passage of biomolecules across the same called the 
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Blood Brain Barrier (BBB) 
1
. The BBB is complex and highly regulated since it screens 
biomolecules based on physicochemical and biochemical features and selectively 
transports them into the brain parenchyma. The BBB does not let biomolecules larger 
than 40 daltons to be transported across into the brain 
2
 and hence is a huge issue for 
delivery of antibody based therapeutics (size of an scFv is 29 kD and that of a full length 
IgG is 150 kD).  It is interesting to note that the BBB is compromised and may be more 
leaky in AD patients when compared with normal brains but still this is not sufficient for 
antibody in the blood to get transported into the brain 
1
. 
Transport across the blood brain barrier (BBB) occurs in two main routes – either 
carrier mediated or receptor mediated transport. In carrier mediated transport, small water 
soluble nutrients like glucose and amino acids are transported across the barrier by 
specific transporters expressed by the solute carrier family of genes. In addition, receptor 
mediated transport systems are employed by the BBB to transport larger endogenous bio-
molecules. Some of these include the insulin receptor and the Transferrin receptor 
3
. This 
pathway has been shown to involve rapid transcytosis based transport across the BBB. 
Exploiting the insulin signaling mechanism Pardridge et al showed that a molecular 
Trojan horse that contains a monoclonal antibody to the insulin receptor can be used to 
rapidly transport material across the BBB 
4
. In addition, the Low-Density Lipoportien 
receptor LRP-1 which is widely expressed in the brain, has also been used to transport 
material across the BBB. The Angiopep sequence patented by Angiochem is a 19 amino 
acid sequence that uses the LRP-1 receptor 
5
 to transport cargo across into the brain. 
Nanomaterials like PBCA have also been shown to use the LRP-1 receptor to cross the 
BBB 
6
. Conjugating antibody therapeutics with PBCA type nanoparticles may enable 
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successful delivery into the brain. On the other hand, Trojan horse approach or Angiopep 
may also be used to delivery material into the BBB.  
 
 
Figure 7.1 Schematic representing the Blood Brain Barrier showing the capillary 
and the tight junctions that make up the Blood Brain Barrier 
7
.  
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7.5 Mouse Models of Alzheimer’s Disease 
After studies of scFv using cell models, in-vivo studies using the iBSEC1 and 
DIA10D scFv is the subsequent step with the characterization. Animal models of 
Alzheimer‟s Disease are usually developed to express mutant forms of APP like Swedish 
APP and Swedish/Indiana APP 
8
. The Tg2576 mouse model is one of the most 
commonly used mouse model in Alzheimer‟s disease and it expresses a Swedish mutated 
APP.  Recently, mice which harbor mutant Presenilin (M126V) and tau (P301L) along 
with mutant APP (Swedish APP) (triple transgenic mice) were developed. 
9
. These 3xTg 
mice are unique since they develop plaques containing deposits of Aβ protein and tangles 
containing deposits of tau protein. Immunoreactivity for anti-tau and anti-Abeta 
antibodies is observed as early as 3 months of age in these mice 
10
. 
 ScFv iBSEC1 and DIA10D will be cloned into viral vectors in order to enable 
intracranial injection and expression of scFv in the brain of transgenic mice expressing 
APP in order to study the effects of the therapeutics on Aβ deposition and behavioral 
changes. Both the scFv will be cloned into an Adeno-associated viral vector (AAV) in 
order to synthesize the virus and inject it intracranially.  Miller T.W. and Messer A. 
previously showed expressing of an scFv targeted against the Huntingtin protein and 
showed expression of scFv in the brain following intracranial injection 
11
. 
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Figure 7.2 Expression of scFv targeted against the Huntingtin protein involved in 
the onset of Huntington‟s Disease after delivery of virus. Expression as an intrabody 
under the Cytomegalovirus promoter results in positive detection using HA tag in mouse 
brains sacrificed at 3 months  
11
. 
 
 
 
157 
7.6 Characterization of Aβ specific scFv 
We also isolated an scFv specific to the N-terminal region of Aβ using FACS 
analysis. The scFv yNAB1 and yNAB2 were both isolated from a human yeast display 
library. Both scFv were characterized to bind Aβ. Immunoblotting will be used to 
confirm that the scFv bind all forms of Aβ.  Scfv that recognize all forms of Aβ may be 
important tools to aid in characterization as a positive control scFv. FACS analysis will 
be used to calculate the Kd value for these scFv 
12
 and the possibility of using RMS value 
for estimation of Kd will also be explored.  
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APPENDIX A 
CELL BASED ASSAYS USED FOR CHARACTERIZATION OF CURCUMIN IN MAMMALIAN CELL 
MODELS OF PARKINSON’S DISEASE 
ROS , Caspase and DNA staining was used to study effect of Curcumin on oligomeric 
aggregates of alpha-synuclein. The antioxidant curcumin was tested for its ability to reduce 
neurotoxicity caused by oligomeric aggregates of alpha synuclein. Similar effects were also 
observed using SHSY-5Y cells overexpressing wild type alpha synuclein-eGFP  as a cell model. 
 
 
Figure A.1 Reduction in ROS levels and Caspase activity in SHSY-5Y cells. (A) Alpha 
synuclein was aggregated in-vitro and 5 day samples (oligomeric aggregates as confirmed by 
AFM) were added to SHSY5Y cells with and without treatment with 4 µM Curcumin at a final 
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concentration of 2µM. ROS levels were measured using the probe DCFH-DA. (b) Using a 
Caspase-3 activity kit, % Caspase activity was observed to decrease with curcumin treated 
oligomeric synuclein.  
 
Figure A.2 Changes in nuclear morphology observed when SHSY-5Y cells were treated 
with samples as mentioned previously, fixed with 4% paraformaldehyde and stained with 
Hoescht dye. (A) Buffer control (B) Synuclein oligomers (C) Synuclein  treated with Curcumin and 
(D) Curcumin alone, showing a reduction in DNA damage after treatment with Curcumin. 
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APPENDIX B 
CHARACTERIZATION OF Α-SECRETASE STIMULATING SCFV aSEC1A  AND CONFORMATION 
SPECIFIC SCFV E1 IN CELL MODELS OF ALZHEIMER’S DISEASE 
Asec1A, an scFv that was affinity matured for specific cleavage of APP or abeta at the α-
secretase site was further characterized in CHO cells over expressing APP with the V717F 
mutation (7PA2 cells) 
 
Figure B.2  Asec1A scFv at a concentration of 250 nM was co-incubated with aggregates 
of 50 µM abeta at different time points and added to SHSY-5Y cells (A) Abeta alone showed a 
characteristic increase in cytotoxicity as measured by LDH release showing oligomer formation 
and aggregation into fibrils. (B) Abeta incubation with Asec1A reduced the toxicity of the abeta 
aggregates. 
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Figure B.2 Oligomer specific scFv E1 and A4 reduce cytotoxicity of abeta in neuronal 
cells. Abeta was aggregated at a concentration of 50 µM and added to SHSY-5Y cells at a final 
concentration of 1 µM with or without incubation with A4 or E1 scFv at 2.5 µM. (A) Abeta alone 
showed a characteristic increase in LDH release (B) incubation with A4 scFv reduced cytotoxicity. 
(C) Incubation with E1 scFv also reduced cytotoxicity of abeta aggregates.  
 
